[
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2026 Apr",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™¼ç‚æ€§ç–¾ç—…çš„æ²»ç™‚ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘ç›¸é—œçš„è‚è‡Ÿæå‚·æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œå°¤å…¶æ˜¯èˆ‡è…¸é“å’Œè‚è‡Ÿå¥åº·æœ‰é—œçš„å•é¡Œã€‚é€™æ¨£çš„ç™¼ç¾å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°å¦‚æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…æ™‚ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡ŸäºŒæ¬¡æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ä¸‹ã€‚é€™é …ç ”ç©¶çš„èƒŒæ™¯æ˜¯ï¼Œå…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œå› æ­¤æœ¬ç ”ç©¶é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œæ—¨åœ¨ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "é€™é …å¯¦é©—ä¸»è¦æ˜¯é‡å°ä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–è‹·ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ é€²è¡Œçš„ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½æŒ‡æ¨™çš„æ”¹å–„ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2è¡¨é”çš„è®ŠåŒ–ã€‚å¯¦é©—ä¸­ä¹Ÿè©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦ç ”ç©¶äº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ï¼Œé€™äº›éƒ½æ˜¯äº†è§£è˜¿è””ç¡«ç´ ä½œç”¨æ©Ÿåˆ¶çš„é‡è¦å› ç´ ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œä¸¦æ”¹å–„è‚åŠŸèƒ½åƒæ•¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·å…¶å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œé€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚è‡Ÿæå‚·ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™¼ç‚æ€§ç–¾ç—…çš„æ²»ç™‚ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘ç›¸é—œçš„è‚è‡Ÿæå‚·æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œå°¤å…¶æ˜¯èˆ‡è…¸é“å’Œè‚è‡Ÿå¥åº·æœ‰é—œçš„å•é¡Œã€‚é€™æ¨£çš„ç™¼ç¾å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°å¦‚æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…æ™‚ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡ŸäºŒæ¬¡æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ä¸‹ã€‚é€™é …ç ”ç©¶çš„èƒŒæ™¯æ˜¯ï¼Œå…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ï¼Œå› æ­¤æœ¬ç ”ç©¶é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œæ—¨åœ¨ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›ç§‘å­¸ä¾æ“šã€‚\n\né€™é …å¯¦é©—ä¸»è¦æ˜¯é‡å°ä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–è‹·ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ é€²è¡Œçš„ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½æŒ‡æ¨™çš„æ”¹å–„ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2è¡¨é”çš„è®ŠåŒ–ã€‚å¯¦é©—ä¸­ä¹Ÿè©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦ç ”ç©¶äº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ï¼Œé€™äº›éƒ½æ˜¯äº†è§£è˜¿è””ç¡«ç´ ä½œç”¨æ©Ÿåˆ¶çš„é‡è¦å› ç´ ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œä¸¦æ”¹å–„è‚åŠŸèƒ½åƒæ•¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·å…¶å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œé€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ä¾†æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚è‡Ÿæå‚·ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2026 å¹´ 4 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½å°è…¸é“å’Œè‚è‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼é€™æ˜¯æœ€è¿‘ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾çš„å“¦ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼ã€Œè˜¿è””ç¡«ç´ ã€é€™å€‹æˆåˆ†ï¼Œæ¢è¨å®ƒå°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆé€™æ˜¯ä¸€ç¨®è…¸é“ç–¾ç—…ï¼‰ç›¸é—œè‚è‡Ÿæå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶äººå“¡ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›å°é¼ çš„è…¸é“å’Œè‚è‡Ÿå¥åº·ã€‚\n\nå¯¦é©—ä¸­ï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿæå‚·ï¼Œé‚„èƒ½æ”¹å–„è‚åŠŸèƒ½ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜è…¸é“å…§çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œé€™å°è…¸é“å¥åº·éå¸¸é‡è¦ï¼\n\né€™è£¡æœ‰å¹¾å€‹é‡é»åˆ†äº«çµ¦å¤§å®¶ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n2. å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²èˆ‡è…¸é“å’Œè‚è‡Ÿç›¸é—œçš„ç–¾ç—…ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æœªä¾†æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœï¼\n\nå¿«ä¾†å¤šåƒä¸€äº›å¥åº·çš„è”¬èœå§ï¼",
    "image_prompt": "Create a flat design infographic with a light background illustrating the research on sulforaphane. Include symbols of broccoli and sulforaphane, simplified images of experimental subjects like mice, and arrows or flow lines showing the experimental process. Include a section labeled 'Main Results' highlighting protective effects and changes observed, such as reduced intestinal and liver damage.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "41620896",
    "title_en": "Sulforaphane attenuates high-fat diet-induced myocardial injury via AMPK/SIRT1/P65 signaling in mice.",
    "pub_date": "2026 Mar",
    "journal": "Pakistan journal of pharmaceutical sciences",
    "abstract_en": "Obesity-induced metabolic disorders are closely associated with myocardial injury, in which lipid accumulation and chronic inflammation play critical roles. Activation of the AMPK/SIRT1 pathway has been reported to suppress NF-ÎºB-mediated inflammatory responses and protect cardiac function. Sulforaphane (SFN), a bioactive isothiocyanate derived from cruciferous vegetables, exhibits potent metabolic and anti-inflammatory properties; however, its protective effects and underlying mechanisms in obesity-related myocardial injury remain incompletely understood. This study aimed to investigate whether SFN alleviates high-fat diet (HFD)-induced myocardial injury and to elucidate the involvement of the AMPK/SIRT1/NF-ÎºB signaling pathway. Male C57BL/6 mice were fed a normal diet or HFD, with or without SFN treatment, for 16 weeks. Metabolic parameters, serum lipid profiles, myocardial injury markers, inflammatory cytokines and histopathological changes were evaluated. In vitro, palmitic acid-treated H9c2 cardiomyocytes were used to assess the mechanistic role of AMPK/SIRT1 signaling, with pharmacological inhibition of AMPK. SFN significantly reduced body weight, fasting glucose, serum triglycerides, total cholesterol, free fatty acids, and LDL levels in HFD-fed mice. SFN markedly attenuated myocardial structural damage and decreased serum CK, CK-MB, and cTnI levels. Inflammatory cytokines (TNF-Î±, IL-1Î², IL-6) were suppressed at both serum and myocardial mRNA levels. Mechanistically, SFN enhanced AMPK phosphorylation and SIRT1 expression while inhibiting p65 phosphorylation. In vitro, AMPK inhibition reversed the anti-inflammatory effects of SFN. SFN effectively alleviates HFD-induced myocardial injury by activating the AMPK/SIRT1 pathway and suppressing NF-ÎºB-mediated inflammation, highlighting its potential as a therapeutic agent for obesity-related cardiac injury.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚¥èƒ–å¼•èµ·çš„å¿ƒè‡Ÿæå‚·æ–¹é¢ã€‚è‚¥èƒ–ä¸åƒ…æœƒå°è‡´é«”é‡å¢åŠ ï¼Œé‚„å¯èƒ½å¼•ç™¼ä¸€ç³»åˆ—ä»£è¬ç–¾ç—…ï¼Œé€™äº›ç–¾ç—…æœƒå°å¿ƒè‡Ÿé€ æˆå‚·å®³ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹å–„ä»£è¬ç‹€æ³å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å¿ƒè‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿèª¿æ•´æˆ–è£œå……æŸäº›å¤©ç„¶æˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚¥èƒ–å°å¿ƒè‡Ÿçš„è² é¢å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²å¿ƒè‡Ÿå¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨çš„æ˜¯è‚¥èƒ–å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿï¼Œä¸¦è©¦åœ–æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­çš„ä½œç”¨ã€‚é€éåˆ†æè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿçš„ä¿è­·æ•ˆæœï¼Œç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—è‚¥èƒ–ç›¸é—œçš„å¿ƒè‡Ÿç–¾ç—…ï¼Œé€™å°æ–¼æ”¹å–„å…¬å…±å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é›„æ€§C57BL/6å°é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºæ­£å¸¸é£²é£Ÿçµ„å’Œé«˜è„‚é£²é£Ÿçµ„ï¼Œä¸¦åœ¨æŸäº›çµ„åˆ¥ä¸­æ·»åŠ äº†è˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ16é€±ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ä»£è¬åƒæ•¸ã€è¡€æ¸…è„‚è³ªæª”æ¡ˆã€å¿ƒè‡Ÿæå‚·æ¨™è¨˜ç‰©ã€ç™¼ç‚ç´°èƒå› å­ä»¥åŠçµ„ç¹”ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨äº†ç¶“æ£•æ«šé…¸è™•ç†çš„H9c2å¿ƒè‚Œç´°èƒï¼Œä»¥é€²ä¸€æ­¥æ¢è¨AMPK/SIRT1ä¿¡è™Ÿé€šè·¯çš„æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†AMPKçš„è—¥ç†æŠ‘åˆ¶å¯¦é©—ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘é«˜è„‚é£²é£Ÿå°é¼ çš„é«”é‡ã€ç©ºè…¹è¡€ç³–ã€è¡€æ¸…ä¸‰é…¸ç”˜æ²¹è„‚ã€ç¸½è†½å›ºé†‡ã€æ¸¸é›¢è„‚è‚ªé…¸å’Œä½å¯†åº¦è„‚è›‹ç™½æ°´å¹³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„é¡¯è‘—æ¸›è¼•äº†å¿ƒè‡Ÿçš„çµæ§‹æå‚·ï¼Œä¸¦é™ä½äº†è¡€æ¸…ä¸­çš„CKã€CK-MBå’ŒcTnIæ°´å¹³ã€‚ç™¼ç‚ç´°èƒå› å­ï¼ˆå¦‚TNF-Î±ã€IL-1Î²å’ŒIL-6ï¼‰åœ¨è¡€æ¸…å’Œå¿ƒè‡Ÿçš„mRNAæ°´å¹³ä¸Šå‡æœ‰æ‰€æŠ‘åˆ¶ã€‚æ©Ÿåˆ¶ä¸Šï¼Œè˜¿è””ç¡«ç´ ä¿ƒé€²äº†AMPKçš„ç£·é…¸åŒ–å’ŒSIRT1çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶äº†p65çš„ç£·é…¸åŒ–ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»AMPK/SIRT1é€šè·¯å’ŒæŠ‘åˆ¶NF-ÎºBä»‹å°çš„ç™¼ç‚åæ‡‰ï¼Œä¾†æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚¥èƒ–å¼•èµ·çš„å¿ƒè‡Ÿæå‚·æ–¹é¢ã€‚è‚¥èƒ–ä¸åƒ…æœƒå°è‡´é«”é‡å¢åŠ ï¼Œé‚„å¯èƒ½å¼•ç™¼ä¸€ç³»åˆ—ä»£è¬ç–¾ç—…ï¼Œé€™äº›ç–¾ç—…æœƒå°å¿ƒè‡Ÿé€ æˆå‚·å®³ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹å–„ä»£è¬ç‹€æ³å’Œæ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å¿ƒè‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿèª¿æ•´æˆ–è£œå……æŸäº›å¤©ç„¶æˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚¥èƒ–å°å¿ƒè‡Ÿçš„è² é¢å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²å¿ƒè‡Ÿå¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶ç‰¹åˆ¥é—œæ³¨çš„æ˜¯è‚¥èƒ–å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿï¼Œä¸¦è©¦åœ–æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­çš„ä½œç”¨ã€‚é€éåˆ†æè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿçš„ä¿è­·æ•ˆæœï¼Œç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—è‚¥èƒ–ç›¸é—œçš„å¿ƒè‡Ÿç–¾ç—…ï¼Œé€™å°æ–¼æ”¹å–„å…¬å…±å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é›„æ€§C57BL/6å°é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºæ­£å¸¸é£²é£Ÿçµ„å’Œé«˜è„‚é£²é£Ÿçµ„ï¼Œä¸¦åœ¨æŸäº›çµ„åˆ¥ä¸­æ·»åŠ äº†è˜¿è””ç¡«ç´ ï¼ŒæŒçºŒ16é€±ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ä»£è¬åƒæ•¸ã€è¡€æ¸…è„‚è³ªæª”æ¡ˆã€å¿ƒè‡Ÿæå‚·æ¨™è¨˜ç‰©ã€ç™¼ç‚ç´°èƒå› å­ä»¥åŠçµ„ç¹”ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨äº†ç¶“æ£•æ«šé…¸è™•ç†çš„H9c2å¿ƒè‚Œç´°èƒï¼Œä»¥é€²ä¸€æ­¥æ¢è¨AMPK/SIRT1ä¿¡è™Ÿé€šè·¯çš„æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†AMPKçš„è—¥ç†æŠ‘åˆ¶å¯¦é©—ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘é«˜è„‚é£²é£Ÿå°é¼ çš„é«”é‡ã€ç©ºè…¹è¡€ç³–ã€è¡€æ¸…ä¸‰é…¸ç”˜æ²¹è„‚ã€ç¸½è†½å›ºé†‡ã€æ¸¸é›¢è„‚è‚ªé…¸å’Œä½å¯†åº¦è„‚è›‹ç™½æ°´å¹³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„é¡¯è‘—æ¸›è¼•äº†å¿ƒè‡Ÿçš„çµæ§‹æå‚·ï¼Œä¸¦é™ä½äº†è¡€æ¸…ä¸­çš„CKã€CK-MBå’ŒcTnIæ°´å¹³ã€‚ç™¼ç‚ç´°èƒå› å­ï¼ˆå¦‚TNF-Î±ã€IL-1Î²å’ŒIL-6ï¼‰åœ¨è¡€æ¸…å’Œå¿ƒè‡Ÿçš„mRNAæ°´å¹³ä¸Šå‡æœ‰æ‰€æŠ‘åˆ¶ã€‚æ©Ÿåˆ¶ä¸Šï¼Œè˜¿è””ç¡«ç´ ä¿ƒé€²äº†AMPKçš„ç£·é…¸åŒ–å’ŒSIRT1çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶äº†p65çš„ç£·é…¸åŒ–ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»AMPK/SIRT1é€šè·¯å’ŒæŠ‘åˆ¶NF-ÎºBä»‹å°çš„ç™¼ç‚åæ‡‰ï¼Œä¾†æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPakistan journal of pharmaceutical sciencesã€‹æ–¼ 2026 å¹´ 3 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„ç¥å¥‡æˆåˆ†ï¼Œå¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©å–”ï¼é€™ç¯‡ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•æ¸›è¼•é«˜è„‚é£²é£Ÿå°å¿ƒè‡Ÿçš„æå‚·ï¼Œé€™å°è‚¥èƒ–å•é¡Œç‰¹åˆ¥é‡è¦ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†å°é¼ ï¼Œåˆ†æˆæ­£å¸¸é£²é£Ÿå’Œé«˜è„‚é£²é£Ÿå…©çµ„ï¼Œéƒ¨åˆ†å°é¼ é‚„æ·»åŠ äº†è˜¿è””ç¡«ç´ ï¼ŒæŒçºŒäº†16é€±ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…å¹«åŠ©å°é¼ æ¸›å°‘é«”é‡ï¼Œé‚„æ”¹å–„äº†è¡€ç³–å’Œè†½å›ºé†‡æ°´å¹³ï¼Œå°å¿ƒè‡Ÿçš„ä¿è­·æ•ˆæœä¹Ÿç›¸ç•¶æ˜é¡¯ï¼é€™æ„å‘³è‘—ï¼Œé€éèª¿æ•´é£²é£Ÿæˆ–è£œå……ä¸€äº›å¤©ç„¶æˆåˆ†ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ›´å¥½åœ°ä¿è­·å¿ƒè‡Ÿå¥åº·ã€‚  \n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š  \n1. è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘é«”é‡å’Œæ”¹å–„è¡€è„‚ã€‚  \n2. æ¸›è¼•å¿ƒè‡Ÿçµæ§‹æå‚·ï¼Œé™ä½ç™¼ç‚åæ‡‰ã€‚  \n3. å¯èƒ½é€éç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·å¿ƒè‡Ÿã€‚  \n\nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒå¿ƒè‡Ÿå¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main findings of a study on the protective effects of sulforaphane from radishes against heart damage caused by high-fat diets. Include simplified illustrations of radishes or broccoli to symbolize sulforaphane, representations of experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results such as weight loss, improved blood lipid levels, and reduced inflammation.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‡Ÿç—… Heart Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41620896/"
  },
  {
    "id": "41565088",
    "title_en": "Sulforaphane attenuates HFD-induced enteritis in yellow river carp by restoring immune homeostasis, repairing intestinal barrier, and modulating gut microbiota.",
    "pub_date": "2026 Mar",
    "journal": "Fish & shellfish immunology",
    "abstract_en": "High-fat diets (HFD) exacerbate intestinal health risks in aquaculture. This study evaluated effects of dietary sulforaphane (SFN) supplementation on intestinal morphology, biochemistry, microbiota, and metabolism in Yellow River carp (Cyprinus carpio haematopterus) fed HFD. Five isoprotein diets diets were formulated: control (CN, 6Â % lipid), HFD (12.29Â % lipid), and HFD with 10 (HS10), 15 (HS15), or 20 (HS20) mg/kg SFN. Results demonstrated that HFD induced marked intestinal inflammation featuring villi deformation, oxidative stress, epithelial exfoliation, mitochondrial swelling, significantly elevated pro-inflammatory cytokines (TNF-Î±/IL-1Î²/IL-6; pÂ <Â 0.05), and downregulated tight junction protein genes (Occludin/ZO-1/Claudin-3; pÂ <Â 0.05), concomitant with microbial dysbiosis (Proteobacteria dominance>70Â %, reduced Cetobacterium) and disrupted metabolic pathways (amino acid imbalance). SFN supplementation significantly enhanced antioxidant enzyme activities (SOD/CAT/GSH-Px, pÂ <Â 0.05), peaking in HS15, which also exhibited minimized pro-inflammatory cytokines and maximized tight junction expression (pÂ <Â 0.05). Furthermore, 16S rRNA gene sequencing of the gut microbiota indicated that SFN restored microbial homeostasis, notably by increasing the abundance of Cetobacterium. Metabolomic analysis based on KEGG enrichment revealed that these beneficial effects were associated with the activation of FoxO signaling, enhanced lysosomal function, and upregulation of coenzyme A biosynthesis. Critically, HS15 demonstrated optimal efficacy across all parameters. Therefore, 15Â mg/kg SFN is identified as the optimal dose to ameliorate intestinal health in Yellow River carp, providing a theoretical basis for functional aquafeed development.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£ŸæœƒåŠ é‡è…¸é“å¥åº·çš„é¢¨éšªï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éé£²é£Ÿè£œå……ä¾†æ”¹å–„è…¸é“å¥åº·ï¼Œå°æ–¼é­šé¡çš„é¤Šæ®–å’Œç®¡ç†è‡³é—œé‡è¦ã€‚é€™ä¸åƒ…èƒ½æé«˜é­šé¡çš„ç”Ÿé•·å’Œå­˜æ´»ç‡ï¼Œé‚„å¯èƒ½å°æ•´å€‹æ°´ç”¢é¤Šæ®–æ¥­çš„å¯æŒçºŒç™¼å±•æœ‰æ­£é¢å½±éŸ¿ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥åœ°äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„æ°´ç”¢å‹•ç‰©çš„å¥åº·ï¼Œé€²è€Œé™ä½ç–¾ç—…çš„ç™¼ç”Ÿç‡ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°æ–¼é«˜è„‚é£²é£Ÿï¼ˆHFDï¼‰ä¸‹çš„é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é«˜è„‚é£²é£Ÿå¦‚ä½•å½±éŸ¿é­šé¡çš„è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æƒ…æ³ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ”¹å–„å› é«˜è„‚é£²é£Ÿå¼•èµ·çš„è…¸é“ç‚ç—‡å’Œå…¶ä»–å¥åº·å•é¡Œï¼Œä¸¦è©•ä¼°å…¶æ½›åœ¨çš„ä¿å¥æ•ˆæœã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„è›‹ç™½è³ªé£²é£Ÿï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ï¼ˆCNï¼Œå«6%è„‚è‚ªï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆHFDï¼Œå«12.29%è„‚è‚ªï¼‰ä»¥åŠä¸‰å€‹ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ è£œå……çµ„ï¼ˆHS10ã€HS15å’ŒHS20ï¼Œåˆ†åˆ¥ç‚ºæ¯å…¬æ–¤10ã€15å’Œ20æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›é£²é£Ÿå°é»ƒæ²³é¯‰é­šçš„è…¸é“å½¢æ…‹ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠä»£è¬é€”å¾‘çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„ç”ŸåŒ–åˆ†æå’ŒåŸºå› æ¸¬åºï¼Œä»¥è©•ä¼°è…¸é“å¥åº·çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç‚ç—‡ã€æ°§åŒ–å£“åŠ›å’Œå¾®ç”Ÿç‰©å¤±èª¿ï¼Œè€Œè£œå……è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ã€‚ç‰¹åˆ¥æ˜¯15æ¯«å…‹æ¯å…¬æ–¤çš„è˜¿è””ç¡«ç´ åŠ‘é‡åœ¨æ‰€æœ‰åƒæ•¸ä¸­è¡¨ç¾æœ€ä½³ï¼Œèƒ½æé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ä¿ƒç‚ç´°èƒå› å­ï¼Œä¸¦ä¿ƒé€²ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åŸºå› æ¸¬åºçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œç‰¹åˆ¥æ˜¯å¢åŠ äº†Cetobacteriumçš„è±åº¦ã€‚é€™äº›çµæœç‚ºæ°´ç”¢é£¼æ–™çš„åŠŸèƒ½æ€§é–‹ç™¼æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£ŸæœƒåŠ é‡è…¸é“å¥åº·çš„é¢¨éšªï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éé£²é£Ÿè£œå……ä¾†æ”¹å–„è…¸é“å¥åº·ï¼Œå°æ–¼é­šé¡çš„é¤Šæ®–å’Œç®¡ç†è‡³é—œé‡è¦ã€‚é€™ä¸åƒ…èƒ½æé«˜é­šé¡çš„ç”Ÿé•·å’Œå­˜æ´»ç‡ï¼Œé‚„å¯èƒ½å°æ•´å€‹æ°´ç”¢é¤Šæ®–æ¥­çš„å¯æŒçºŒç™¼å±•æœ‰æ­£é¢å½±éŸ¿ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥åœ°äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„æ°´ç”¢å‹•ç‰©çš„å¥åº·ï¼Œé€²è€Œé™ä½ç–¾ç—…çš„ç™¼ç”Ÿç‡ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°æ–¼é«˜è„‚é£²é£Ÿï¼ˆHFDï¼‰ä¸‹çš„é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é«˜è„‚é£²é£Ÿå¦‚ä½•å½±éŸ¿é­šé¡çš„è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æƒ…æ³ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ”¹å–„å› é«˜è„‚é£²é£Ÿå¼•èµ·çš„è…¸é“ç‚ç—‡å’Œå…¶ä»–å¥åº·å•é¡Œï¼Œä¸¦è©•ä¼°å…¶æ½›åœ¨çš„ä¿å¥æ•ˆæœã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„è›‹ç™½è³ªé£²é£Ÿï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ï¼ˆCNï¼Œå«6%è„‚è‚ªï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆHFDï¼Œå«12.29%è„‚è‚ªï¼‰ä»¥åŠä¸‰å€‹ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ è£œå……çµ„ï¼ˆHS10ã€HS15å’ŒHS20ï¼Œåˆ†åˆ¥ç‚ºæ¯å…¬æ–¤10ã€15å’Œ20æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†é€™äº›é£²é£Ÿå°é»ƒæ²³é¯‰é­šçš„è…¸é“å½¢æ…‹ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠä»£è¬é€”å¾‘çš„å½±éŸ¿ï¼Œä¸¦é€²è¡Œäº†ç›¸é—œçš„ç”ŸåŒ–åˆ†æå’ŒåŸºå› æ¸¬åºï¼Œä»¥è©•ä¼°è…¸é“å¥åº·çš„è®ŠåŒ–ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç‚ç—‡ã€æ°§åŒ–å£“åŠ›å’Œå¾®ç”Ÿç‰©å¤±èª¿ï¼Œè€Œè£œå……è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ã€‚ç‰¹åˆ¥æ˜¯15æ¯«å…‹æ¯å…¬æ–¤çš„è˜¿è””ç¡«ç´ åŠ‘é‡åœ¨æ‰€æœ‰åƒæ•¸ä¸­è¡¨ç¾æœ€ä½³ï¼Œèƒ½æé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ä¿ƒç‚ç´°èƒå› å­ï¼Œä¸¦ä¿ƒé€²ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åŸºå› æ¸¬åºçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œç‰¹åˆ¥æ˜¯å¢åŠ äº†Cetobacteriumçš„è±åº¦ã€‚é€™äº›çµæœç‚ºæ°´ç”¢é£¼æ–™çš„åŠŸèƒ½æ€§é–‹ç™¼æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFish & shellfish immunologyã€‹æ–¼ 2026 å¹´ 3 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸åƒ…å½±éŸ¿æˆ‘å€‘è‡ªå·±ï¼Œé‚„æœƒå½±éŸ¿æ°´ä¸­çš„ç”Ÿç‰©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œæ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å¤©ç„¶æˆåˆ†ï¼Œä¾†è‡ªè”¬èœå¦‚é’èŠ±æ¤°èœï¼‰å°é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡ç™¼ç¾ï¼Œé«˜è„‚é£²é£Ÿæœƒè®“é­šçš„è…¸é“å‡ºç¾ç‚ç—‡å’Œå…¶ä»–å¥åº·å•é¡Œï¼Œä½†å¦‚æœåŠ ä¸Šè˜¿è””ç¡«ç´ ï¼Œæƒ…æ³å°±æœƒå¥½è½‰ï¼\n\né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘çµ¦é­šæä¾›äº†ä¸åŒçš„é£²é£Ÿï¼ŒåŒ…æ‹¬é«˜è„‚é£²é£Ÿå’Œæ·»åŠ äº†ä¸åŒåŠ‘é‡è˜¿è””ç¡«ç´ çš„é£²é£Ÿï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„è…¸é“å¥åº·ç‹€æ³ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘è…¸é“ç‚ç—‡ï¼Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œé‚„èƒ½å¹«åŠ©è…¸é“å¾®ç”Ÿç‰©æ¢å¾©å¹³è¡¡ã€‚\n\né€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ äº†è§£ï¼š\n- é«˜è„‚é£²é£Ÿæœƒå½±éŸ¿é­šçš„è…¸é“å¥åº·ã€‚\n- è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è…¸é“ç‚ç—‡å’Œæ°§åŒ–å£“åŠ›ã€‚\n- 15æ¯«å…‹çš„è˜¿è””ç¡«ç´ è¡¨ç¾æœ€ä½³ï¼Œèƒ½ä¿ƒé€²è…¸é“å¾®ç”Ÿç‰©çš„å¹³è¡¡ã€‚\n\né€™ä¸åƒ…å°é­šé¡çš„å¥åº·æœ‰å¹«åŠ©ï¼Œä¹Ÿèƒ½ä¿ƒé€²æ°´ç”¢é¤Šæ®–çš„å¯æŒçºŒç™¼å±•ï¼",
    "image_prompt": "Create an educational infographic that illustrates the experiment and main findings of the study on the effects of sulforaphane (from vegetables like broccoli) on the gut health of fish. Use a flat design style with a white or light-colored background and soft color palette. Include simplified icons representing sulforaphane and experimental subjects like fish. Show arrows or flow lines to indicate the steps of the experiment. Add a section that highlights the main results, such as improvements in gut inflammation and microbial balance.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“ç‚ç—‡ Intestinal Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41565088/"
  },
  {
    "id": "41649614",
    "title_en": "Sulforaphane-Mediated Multitarget Therapeutic Effects in Methylmercury-Induced ALS-Like Pathology: Comparative Analysis and Multifaceted Approach to Neuroprotection and Systemic Recovery.",
    "pub_date": "2026 Feb",
    "journal": "Molecular neurobiology",
    "abstract_en": "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by motor neuron loss driven by oxidative stress, neuroinflammation, and dysregulated survival signaling. The objective of this study was to evaluate the neuroprotective efficacy and safety of sulforaphane (SUFP) in a methylmercury (MMHgâº)-induced preclinical rat model of ALS, with comparison to omaveloxolone (OVX) and dimethyl fumarate (DIMT). SUFP treatment, particularly at 4Â mg/kg, significantly restored antioxidant defense mechanisms through upregulation of Nrf2, HO-1, and SIRT1 while suppressing pro-inflammatory cytokines (IL-1Î², TNF-Î±), apoptotic markers (Bax, caspase-3), and stress-related signaling pathways including p75NTR, PI3K/Akt, and MAPKs. These molecular effects translated into meaningful functional recovery, as evidenced by improvements in grip strength, locomotor performance, spatial memory, and depressive-like behavior. Histopathological evaluation demonstrated attenuation of demyelination and preservation of neuronal architecture in cortical, hippocampal, and cerebellar regions. Beyond central neuroprotection, SUFP exerted systemic benefits by normalizing hepatic enzymes, improving skeletal muscle integrity, restoring redox balance, stabilizing neurofilament and myelin-associated proteins, and correcting hematological alterations. Comparative analysis revealed that SUFP conferred superior neuroprotection with a favorable safety profile relative to OVX and, although slightly less efficacious than DIMT, exhibited reduced systemic toxicity. Molecular docking further supported SUFP's interaction with Nrf2-Keap1 targets, reinforcing its antioxidant and anti-inflammatory mechanisms. Collectively, these findings identify SUFP as a multifaceted and well-tolerated therapeutic candidate for ALS, supporting its further translational and clinical evaluation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…å¦‚è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚ALSæ˜¯ä¸€ç¨®æ¼¸é€²æ€§çš„ç¥ç¶“ç³»çµ±ç–¾ç—…ï¼Œæœƒå°è‡´é‹å‹•ç¥ç¶“å…ƒçš„å–ªå¤±ï¼Œä¸¦èˆ‡æ°§åŒ–å£“åŠ›å’Œç¥ç¶“ç™¼ç‚æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥çœ‹åˆ°ï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³éç¨‹ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªï¼Œé€™å°æ–¼æœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ä¸€ç¨®ç”±ç”²åŸºæ±èª˜å°çš„ALSå‰è‡¨åºŠå¤§é¼ æ¨¡å‹ä¸­çš„ç¥ç¶“ä¿è­·æ•ˆæœåŠå®‰å…¨æ€§ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„å› ALSå¼•èµ·çš„ç¥ç¶“æå‚·ï¼Œä¸¦èˆ‡å…¶ä»–å…©ç¨®è—¥ç‰©ï¼ˆomaveloxoloneå’Œdimethyl fumarateï¼‰é€²è¡Œæ¯”è¼ƒã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æ¢ç´¢æ–°ç™‚æ³•çš„æ½›åŠ›ï¼Œä¹Ÿèƒ½æä¾›å°ç¾æœ‰æ²»ç™‚çš„æ·±å…¥äº†è§£ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç”²åŸºæ±èª˜å°çš„ALSå¤§é¼ æ¨¡å‹ï¼Œä¸¦å°‡å¤§é¼ åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œæ¥å—ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯4 mg/kgçš„åŠ‘é‡ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›å¤§é¼ çš„æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ã€ç‚ç—‡æ¨™è¨˜ã€é‹å‹•èƒ½åŠ›ã€è¨˜æ†¶åŠ›å’Œè¡Œç‚ºè¡¨ç¾ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†çµ„ç¹”å­¸è©•ä¼°ï¼Œä»¥è§€å¯Ÿç¥ç¶“çµæ§‹çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šæ–¹é¢é¡¯ç¤ºå‡ºç¥ç¶“ä¿è­·çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„é‹å‹•èƒ½åŠ›å’Œè¨˜æ†¶åŠ›æ–¹é¢ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æé«˜æŠ—æ°§åŒ–é…¶çš„è¡¨ç¾ï¼Œæ¸›å°‘ç‚ç—‡å› å­å’Œç´°èƒå‡‹äº¡æ¨™è¨˜ï¼Œä¸¦æ”¹å–„ç¥ç¶“çµæ§‹çš„å®Œæ•´æ€§ã€‚æ­¤å¤–ï¼Œèˆ‡å…¶ä»–è—¥ç‰©ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ å±•ç¾å‡ºè¼ƒå¥½çš„å®‰å…¨æ€§å’Œè¼ƒä½çš„ç³»çµ±æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯åœ¨ALSçš„è‡¨åºŠæ‡‰ç”¨ä¸Šã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…å¦‚è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚ALSæ˜¯ä¸€ç¨®æ¼¸é€²æ€§çš„ç¥ç¶“ç³»çµ±ç–¾ç—…ï¼Œæœƒå°è‡´é‹å‹•ç¥ç¶“å…ƒçš„å–ªå¤±ï¼Œä¸¦èˆ‡æ°§åŒ–å£“åŠ›å’Œç¥ç¶“ç™¼ç‚æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥çœ‹åˆ°ï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³éç¨‹ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªï¼Œé€™å°æ–¼æœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ä¸€ç¨®ç”±ç”²åŸºæ±èª˜å°çš„ALSå‰è‡¨åºŠå¤§é¼ æ¨¡å‹ä¸­çš„ç¥ç¶“ä¿è­·æ•ˆæœåŠå®‰å…¨æ€§ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„å› ALSå¼•èµ·çš„ç¥ç¶“æå‚·ï¼Œä¸¦èˆ‡å…¶ä»–å…©ç¨®è—¥ç‰©ï¼ˆomaveloxoloneå’Œdimethyl fumarateï¼‰é€²è¡Œæ¯”è¼ƒã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æ¢ç´¢æ–°ç™‚æ³•çš„æ½›åŠ›ï¼Œä¹Ÿèƒ½æä¾›å°ç¾æœ‰æ²»ç™‚çš„æ·±å…¥äº†è§£ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç”²åŸºæ±èª˜å°çš„ALSå¤§é¼ æ¨¡å‹ï¼Œä¸¦å°‡å¤§é¼ åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œæ¥å—ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯4 mg/kgçš„åŠ‘é‡ã€‚ç ”ç©¶è€…è©•ä¼°äº†é€™äº›å¤§é¼ çš„æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ã€ç‚ç—‡æ¨™è¨˜ã€é‹å‹•èƒ½åŠ›ã€è¨˜æ†¶åŠ›å’Œè¡Œç‚ºè¡¨ç¾ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†çµ„ç¹”å­¸è©•ä¼°ï¼Œä»¥è§€å¯Ÿç¥ç¶“çµæ§‹çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šæ–¹é¢é¡¯ç¤ºå‡ºç¥ç¶“ä¿è­·çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„é‹å‹•èƒ½åŠ›å’Œè¨˜æ†¶åŠ›æ–¹é¢ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æé«˜æŠ—æ°§åŒ–é…¶çš„è¡¨ç¾ï¼Œæ¸›å°‘ç‚ç—‡å› å­å’Œç´°èƒå‡‹äº¡æ¨™è¨˜ï¼Œä¸¦æ”¹å–„ç¥ç¶“çµæ§‹çš„å®Œæ•´æ€§ã€‚æ­¤å¤–ï¼Œèˆ‡å…¶ä»–è—¥ç‰©ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ å±•ç¾å‡ºè¼ƒå¥½çš„å®‰å…¨æ€§å’Œè¼ƒä½çš„ç³»çµ±æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯åœ¨ALSçš„è‡¨åºŠæ‡‰ç”¨ä¸Šã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular neurobiologyã€‹æ–¼ 2026 å¹´ 2 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œåƒé’èŠ±æ¤°èœé€™æ¨£çš„è”¬èœå¯èƒ½å°æˆ‘å€‘çš„è…¦éƒ¨å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼æŸäº›è”¬èœä¸­çš„å¤©ç„¶åŒ–åˆç‰©ï¼‰å¯èƒ½å°ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…å¦‚è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰æœ‰ä¿è­·ä½œç”¨ã€‚é€™æ˜¯ä¸€ç¨®å½±éŸ¿é‹å‹•ç¥ç¶“å…ƒçš„ç–¾ç—…ï¼Œæœƒè®“äººè®Šå¾—è¶Šä¾†è¶Šç„¡æ³•æ§åˆ¶è‡ªå·±çš„è‚Œè‚‰ã€‚\n\né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘åœ¨ä¸€å€‹ç‰¹åˆ¥çš„å¯¦é©—ä¸­ï¼Œä½¿ç”¨äº†ä¸€ç¨®ç”±ç”²åŸºæ±èª˜å°çš„ALSå¤§é¼ æ¨¡å‹ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›å¤§é¼ çš„ç¥ç¶“æå‚·ã€‚ä»–å€‘å°‡å¤§é¼ åˆ†æˆå¹¾çµ„ï¼Œçµ¦äºˆä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€ç‚ç—‡ç‹€æ³å’Œé‹å‹•èƒ½åŠ›ç­‰ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¼¼ä¹èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„è¡¨ç¾ï¼Œæ¸›å°‘ç‚ç—‡ï¼Œä¸¦æ”¹å–„é‹å‹•èƒ½åŠ›å’Œè¨˜æ†¶åŠ›ã€‚èˆ‡å…¶ä»–è—¥ç‰©ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ çš„å®‰å…¨æ€§ä¹Ÿç›¸å°è¼ƒé«˜ï¼Œé€™è®“äººå°æœªä¾†çš„æ²»ç™‚é¸æ“‡å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æ”¹å–„é‹å‹•èƒ½åŠ›å’Œè¨˜æ†¶åŠ›ã€‚\n2. å®ƒèƒ½æé«˜æŠ—æ°§åŒ–é…¶ï¼Œæ¸›å°‘ç‚ç—‡ã€‚\n3. ç›¸è¼ƒæ–¼å…¶ä»–è—¥ç‰©ï¼Œè˜¿è””ç¡«ç´ å±•ç¾å‡ºè¼ƒå¥½çš„å®‰å…¨æ€§ã€‚",
    "image_prompt": "Create an infographic illustrating the experiment and main findings of a study on sulforaphane's effects on ALS. Include simplified icons of broccoli or sulforaphane, experimental subjects like rats, and arrows or flow lines to show the steps of the experiment. Include a section highlighting the main results, such as protective effects on movement and memory, and reduced inflammation.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ Amyotrophic Lateral Sclerosis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41649614/"
  },
  {
    "id": "41651260",
    "title_en": "Mining of key genes involved in the sulforaphane biosynthetic pathway of moringa and cloning, expression, and functional verification of MoMYR1.",
    "pub_date": "2026 Feb",
    "journal": "International journal of biological macromolecules",
    "abstract_en": "Moringa oleifera, a plant of significant medicinal and edible value, is renowned for its bioactive compound isothiocyanates (ITCs) with multiple health benefits. This study investigates the biosynthetic mechanism of ITCs in M. oleifera. Local BLAST alignment and KEGG pathway analysis of the Moringa genome identified nine key genes encoding six enzymes-BCAT, CYP79F1, CYP83A1, UGT, SOT, and MYR-potentially involved in ITCs biosynthesis. Expression correlation analysis showed that only myrosinase genes MoMYR1 and MoMYR3 exhibited significant positive correlation with sulforaphane content across tissues (pâ€¯<â€¯0.05). The MoMYR1 gene (GeneBank: PP738617) was successfully cloned for the first time. Heterologous expression in Escherichia coli BL21 produced recombinant MoMYR1 protein, while expression in Pichia pastoris GS115 yielded no detectable MoMYR3 protein. Molecular docking revealed a binding energy of -8.0â€¯kcal/mol between the protein and substrate, indicating strong affinity. In vitro enzymatic assays demonstrated that recombinant MoMYR1 catalyzed Sinigrin and GL with specific activities of 0.2565 and 0.2447â€¯Î¼molÂ·(minÂ·mg)<sup>-1</sup>, and catalytic efficiencies of 30.17 and 28.79â€¯UÂ·g<sup>-1</sup>, respectively. LC-MS analysis confirmed the conversion of GL to sulforaphane by heterologously expressed MoMYR1. This study identifies MoMYR1 as a key enzyme gene in ITCs biosynthesis in Moringa oleifera, providing a theoretical foundation and critical target for elucidating regulatory mechanisms and developing green production strategies.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå¾æŸäº›æ¤ç‰©ä¸­æå–çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç›Šã€‚ä¾‹å¦‚ï¼Œé€™é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®åç‚ºã€Œè¾£æœ¨ã€çš„æ¤ç‰©ï¼Œé€™ç¨®æ¤ç‰©å«æœ‰çš„åŒ–åˆç‰©å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¥åº·ç‹€æ³ï¼Œç”šè‡³åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½å°ç–¾ç—…çš„é é˜²æœ‰æ­£é¢å½±éŸ¿ã€‚é€™æé†’æˆ‘å€‘ï¼Œé€éé£²é£Ÿæ”å–å¤©ç„¶æ¤ç‰©æˆåˆ†ï¼Œå¯èƒ½æ˜¯ä¿ƒé€²å¥åº·çš„ä¸€ç¨®æ–¹å¼ï¼Œå°¤å…¶æ˜¯é‚£äº›å¯Œå«ç”Ÿç‰©æ´»æ€§æˆåˆ†çš„æ¤ç‰©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è¾£æœ¨ä¸­ä¸€ç¨®åç‚ºç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©çš„åˆæˆæ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©æ˜¯å¦‚ä½•åœ¨è¾£æœ¨ä¸­åˆæˆçš„ï¼Œä¸¦ä¸”æ‰¾å‡ºèˆ‡å…¶åˆæˆç›¸é—œçš„åŸºå› å’Œé…¶ã€‚é€™äº›ç•°ç¡«æ°°é…¸é…¯è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œå› æ­¤äº†è§£å…¶åˆæˆéç¨‹å°æ–¼æœªä¾†çš„æ‡‰ç”¨å’Œç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†è¾£æœ¨çš„åŸºå› çµ„é€²è¡Œäº†æœ¬åœ°BLASTæ¯”å°å’ŒKEGGé€šè·¯åˆ†æï¼Œæ‰¾å‡ºäº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› ç·¨ç¢¼äº†å…­ç¨®å¯èƒ½åƒèˆ‡ITCsåˆæˆçš„é…¶ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†åŸºå› è¡¨é”ç›¸é—œæ€§åˆ†æï¼Œç™¼ç¾åªæœ‰å…©å€‹åç‚ºMoMYR1å’ŒMoMYR3çš„åŸºå› èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰é¡¯è‘—æ­£ç›¸é—œã€‚é€™é …ç ”ç©¶ä¸­ï¼ŒMoMYR1åŸºå› é¦–æ¬¡è¢«å…‹éš†å‡ºä¾†ï¼Œä¸¦åœ¨å¤§è…¸æ¡¿èŒä¸­è¡¨é”ä»¥ç”¢ç”Ÿé‡çµ„è›‹ç™½ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œé‡çµ„çš„MoMYR1è›‹ç™½åœ¨é«”å¤–é…¶ä¿ƒåæ‡‰ä¸­èƒ½æœ‰æ•ˆå‚¬åŒ–æŸäº›åº•ç‰©ï¼Œä¸¦ä¸”é€šéLC-MSåˆ†æç¢ºèªäº†å…¶èƒ½å°‡ä¸€ç¨®åŒ–åˆç‰©è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ ã€‚é€™è¡¨æ˜MoMYR1åœ¨è¾£æœ¨çš„ITCsåˆæˆä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œç‚ºæœªä¾†ç ”ç©¶é€™äº›åŒ–åˆç‰©çš„èª¿æ§æ©Ÿåˆ¶å’Œé–‹ç™¼ç¶ è‰²ç”Ÿç”¢ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå¾æŸäº›æ¤ç‰©ä¸­æå–çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç›Šã€‚ä¾‹å¦‚ï¼Œé€™é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®åç‚ºã€Œè¾£æœ¨ã€çš„æ¤ç‰©ï¼Œé€™ç¨®æ¤ç‰©å«æœ‰çš„åŒ–åˆç‰©å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¥åº·ç‹€æ³ï¼Œç”šè‡³åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½å°ç–¾ç—…çš„é é˜²æœ‰æ­£é¢å½±éŸ¿ã€‚é€™æé†’æˆ‘å€‘ï¼Œé€éé£²é£Ÿæ”å–å¤©ç„¶æ¤ç‰©æˆåˆ†ï¼Œå¯èƒ½æ˜¯ä¿ƒé€²å¥åº·çš„ä¸€ç¨®æ–¹å¼ï¼Œå°¤å…¶æ˜¯é‚£äº›å¯Œå«ç”Ÿç‰©æ´»æ€§æˆåˆ†çš„æ¤ç‰©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è¾£æœ¨ä¸­ä¸€ç¨®åç‚ºç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©çš„åˆæˆæ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©æ˜¯å¦‚ä½•åœ¨è¾£æœ¨ä¸­åˆæˆçš„ï¼Œä¸¦ä¸”æ‰¾å‡ºèˆ‡å…¶åˆæˆç›¸é—œçš„åŸºå› å’Œé…¶ã€‚é€™äº›ç•°ç¡«æ°°é…¸é…¯è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œå› æ­¤äº†è§£å…¶åˆæˆéç¨‹å°æ–¼æœªä¾†çš„æ‡‰ç”¨å’Œç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†è¾£æœ¨çš„åŸºå› çµ„é€²è¡Œäº†æœ¬åœ°BLASTæ¯”å°å’ŒKEGGé€šè·¯åˆ†æï¼Œæ‰¾å‡ºäº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› ç·¨ç¢¼äº†å…­ç¨®å¯èƒ½åƒèˆ‡ITCsåˆæˆçš„é…¶ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†åŸºå› è¡¨é”ç›¸é—œæ€§åˆ†æï¼Œç™¼ç¾åªæœ‰å…©å€‹åç‚ºMoMYR1å’ŒMoMYR3çš„åŸºå› èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰é¡¯è‘—æ­£ç›¸é—œã€‚é€™é …ç ”ç©¶ä¸­ï¼ŒMoMYR1åŸºå› é¦–æ¬¡è¢«å…‹éš†å‡ºä¾†ï¼Œä¸¦åœ¨å¤§è…¸æ¡¿èŒä¸­è¡¨é”ä»¥ç”¢ç”Ÿé‡çµ„è›‹ç™½ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œé‡çµ„çš„MoMYR1è›‹ç™½åœ¨é«”å¤–é…¶ä¿ƒåæ‡‰ä¸­èƒ½æœ‰æ•ˆå‚¬åŒ–æŸäº›åº•ç‰©ï¼Œä¸¦ä¸”é€šéLC-MSåˆ†æç¢ºèªäº†å…¶èƒ½å°‡ä¸€ç¨®åŒ–åˆç‰©è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ ã€‚é€™è¡¨æ˜MoMYR1åœ¨è¾£æœ¨çš„ITCsåˆæˆä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œç‚ºæœªä¾†ç ”ç©¶é€™äº›åŒ–åˆç‰©çš„èª¿æ§æ©Ÿåˆ¶å’Œé–‹ç™¼ç¶ è‰²ç”Ÿç”¢ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational journal of biological macromoleculesã€‹æ–¼ 2026 å¹´ 2 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›æ¤ç‰©è£¡é¢è—è‘—å°å¥åº·æœ‰ç›Šçš„ç§˜å¯†ï¼é€™æ¬¡æˆ‘å€‘è¦èŠèŠã€Œè¾£æœ¨ã€ï¼Œé€™ç¨®æ¤ç‰©ä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¥åº·å“¦ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è¾£æœ¨è£¡çš„ä¸€ç¨®å«åšç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„åŒ–åˆç‰©ã€‚é€™äº›åŒ–åˆç‰©è¢«èªç‚ºæœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†æˆ‘å€‘é‚„ä¸å¤ªäº†è§£å®ƒå€‘æ˜¯æ€éº¼åˆæˆçš„ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éåˆ†æè¾£æœ¨çš„åŸºå› ï¼Œæ‰¾å‡ºèˆ‡ITCsåˆæˆæœ‰é—œçš„åŸºå› å’Œé…¶ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†è¾£æœ¨çš„åŸºå› çµ„ï¼Œç™¼ç¾äº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› å¯èƒ½åƒèˆ‡äº†ITCsçš„åˆæˆã€‚ç‰¹åˆ¥æ˜¯æœ‰å…©å€‹åŸºå› ï¼ˆMoMYR1å’ŒMoMYR3ï¼‰èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰ç›´æ¥é—œä¿‚ï¼é€™æ˜¯MoMYR1åŸºå› é¦–æ¬¡è¢«å…‹éš†å‡ºä¾†ï¼Œä¸¦ä¸”åœ¨å¯¦é©—å®¤ä¸­æˆåŠŸè¡¨é”ã€‚\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶ç™¼ç¾MoMYR1è›‹ç™½åœ¨å¯¦é©—ä¸­èƒ½æœ‰æ•ˆå‚¬åŒ–æŸäº›åŒ–åˆç‰©ï¼Œä¸¦è½‰åŒ–ç‚ºè˜¿è””ç¡«ç´ ï¼Œé€™è®“æˆ‘å€‘å°è¾£æœ¨çš„å¥åº·æ½›åŠ›æœ‰äº†æ›´æ·±çš„äº†è§£ï¼\n\nğŸ” é€™é …ç ”ç©¶çš„é‡é»æ˜¯ï¼š\n1. è¾£æœ¨ä¸­å«æœ‰æœ‰ç›Šå¥åº·çš„åŒ–åˆç‰©ï¼Œå€¼å¾—æˆ‘å€‘é‡è¦–ã€‚\n2. MoMYR1åŸºå› åœ¨è˜¿è””ç¡«ç´ çš„åˆæˆä¸­æ‰®æ¼”é—œéµè§’è‰²ã€‚\n3. ç†è§£é€™äº›éç¨‹æœ‰åŠ©æ–¼æœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experimental methods and main results of a study on Moringa. Use a flat design style with a light background and soft colors. Include symbols for broccoli or compounds like sulforaphane, simplified representations of experimental subjects (like people, animals, or cells), and arrows or flow lines to indicate experimental steps. Include a section labeled 'Main Results' highlighting key findings such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41651260/"
  },
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„é˜²æ²»æ–¹é¢ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æ½°ç˜æ€§çµè…¸ç‚çš„é¢¨éšªã€‚é€™å°æ–¼å¸Œæœ›é€éè‡ªç„¶é£Ÿç‰©ä¾†ä¿ƒé€²å¥åº·çš„äººä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—æ³¨æ„çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ç”¢ç”Ÿä¿è­·ä½œç”¨ï¼Œä»¥åŠé€™ç¨®ä½œç”¨æ˜¯å¦‚ä½•é€éèª¿ç¯€ç‰¹å®šçš„ç´°èƒä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å…©å€‹é‡è¦ä¿¡è™Ÿé€šè·¯æ˜¯Nrf2å’ŒSTAT3ï¼Œé€™äº›é€šè·¯åœ¨ç‚ç—‡åæ‡‰å’Œç´°èƒä¿è­·ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„äº’å‹•é—œä¿‚å°æ–¼ç–¾ç—…çš„æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨é”é™ä½ï¼Œè€ŒSTAT3çš„è¡¨é”å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œä½¿ç”¨Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­è§€å¯Ÿè˜¿è””ç¡«ç´ å°è…¸é“ç—‡ç‹€çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰æƒ…æ³ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼Œä¸¦ä¸”åœ¨æ­£å¸¸å°é¼ ä¸­æé«˜äº†Nrf2å’Œç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ï¼ŒæŠ‘åˆ¶äº†ç‚ç—‡å› å­çš„é‡‹æ”¾ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨Nrf2ç¼ºå¤±çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œæ¸›å°‘äº†æŸäº›ç´°èŒçš„ç›¸å°è±åº¦ï¼Œé€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨å¯èƒ½èˆ‡Nrf2/STAT3ä¿¡è™Ÿé€šè·¯çš„èª¿ç¯€åŠè…¸é“å¾®ç”Ÿç‰©çš„æ”¹è®Šæœ‰é—œã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„é˜²æ²»æ–¹é¢ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½æ½°ç˜æ€§çµè…¸ç‚çš„é¢¨éšªã€‚é€™å°æ–¼å¸Œæœ›é€éè‡ªç„¶é£Ÿç‰©ä¾†ä¿ƒé€²å¥åº·çš„äººä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—æ³¨æ„çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ç”¢ç”Ÿä¿è­·ä½œç”¨ï¼Œä»¥åŠé€™ç¨®ä½œç”¨æ˜¯å¦‚ä½•é€éèª¿ç¯€ç‰¹å®šçš„ç´°èƒä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å…©å€‹é‡è¦ä¿¡è™Ÿé€šè·¯æ˜¯Nrf2å’ŒSTAT3ï¼Œé€™äº›é€šè·¯åœ¨ç‚ç—‡åæ‡‰å’Œç´°èƒä¿è­·ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„äº’å‹•é—œä¿‚å°æ–¼ç–¾ç—…çš„æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨é”é™ä½ï¼Œè€ŒSTAT3çš„è¡¨é”å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œä½¿ç”¨Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­è§€å¯Ÿè˜¿è””ç¡«ç´ å°è…¸é“ç—‡ç‹€çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰æƒ…æ³ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼Œä¸¦ä¸”åœ¨æ­£å¸¸å°é¼ ä¸­æé«˜äº†Nrf2å’Œç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ï¼ŒæŠ‘åˆ¶äº†ç‚ç—‡å› å­çš„é‡‹æ”¾ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨Nrf2ç¼ºå¤±çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„å½±éŸ¿äº†è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œæ¸›å°‘äº†æŸäº›ç´°èŒçš„ç›¸å°è±åº¦ï¼Œé€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨å¯èƒ½èˆ‡Nrf2/STAT3ä¿¡è™Ÿé€šè·¯çš„èª¿ç¯€åŠè…¸é“å¾®ç”Ÿç‰©çš„æ”¹è®Šæœ‰é—œã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½å°è…¸é“å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æˆåˆ†ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®è®“è…¸é“ç™¼ç‚çš„æ…¢æ€§ç—…ï¼Œè®“äººéå¸¸ä¸èˆ’æœã€‚é€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ æ˜¯æ€éº¼ç™¼æ®ä½œç”¨çš„ï¼Œæ–¼æ˜¯ä»–å€‘ä½¿ç”¨äº†å°é¼ å’Œç´°èƒæ¨¡å‹é€²è¡Œå¯¦é©—ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯ä»¥æ”¹å–„å°é¼ çš„è…¸é“ç—‡ç‹€ï¼Œä¸¦ä¸”é‚„èƒ½èª¿ç¯€ä¸€äº›é—œéµçš„ç´°èƒä¿¡è™Ÿé€šè·¯ï¼Œé€™äº›é€šè·¯åœ¨ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚ç ”ç©¶ä¹Ÿé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æé«˜æŸäº›ä¿è­·è›‹ç™½çš„è¡¨é”ï¼Œä¸¦å½±éŸ¿è…¸é“å…§çš„å¾®ç”Ÿç‰©å¤šæ¨£æ€§ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éå¢åŠ é£²é£Ÿä¸­é’èŠ±æ¤°èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æ”¹å–„è…¸é“å¥åº·ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚\n2. å®ƒé€éèª¿ç¯€ç´°èƒä¿¡è™Ÿé€šè·¯ä¾†ç™¼æ®ä½œç”¨ã€‚\n3. å¢åŠ é’èŠ±æ¤°èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼è…¸é“å¥åº·ï¼",
    "image_prompt": "Create a flat design infographic with a light background to explain the experiment and main findings of the study on sulforaphane. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like mice and cells, and arrows or flow lines to represent the experimental steps. Add a section labeled 'Main Findings' highlighting the protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41540706",
    "title_en": "[Sulforaphane reduces reactive astrocyte-mediated neuron apoptosis <i>in vitro</i> by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes].",
    "pub_date": "2026 Jan",
    "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
    "abstract_en": "To explore the effects of sulforaphane (SFN) on AÎ²42-activated U87 astrocyte-mediated apoptosis of SH-SY5Y neurons <i>in vitro</i>. U87 cells treated with different concentrations of AÎ²42, SFN or both were examined for changes in cell activity, IL-6 and TNF-Î± mRNA expression, release of IL-6 and TNF-Î± proteins, and expressions of p-p38, p-p65 and GFAP using CCK-8 assay, RT-qPCR, ELISA and Western blotting. SH-SY5Y neurons were co-cultured with U87 astrocytes treated with AÎ²42 alone or in combination with SFN or SB203580 for 24 h, and the changes in Bax protein expression levels and viability of SH-SY5Y cells were examined. The effects of AÎ²42, SFN, and their combination were also observed in astrocytes isolated from mouse brain tissues, and the indirect effects of astrocyte treatmentt on viability of the co-cultured primary neurons were assessed. The viability of U87 astrocytes increased significantly following treatment with 1.25 Î¼mol/L AÎ²42 but decreased after AÎ²42 treatment above 5 Î¼mol/L. SFN treatments for 24 h below 5 Î¼mol/L did not significantly affect U87 cell viability. AÎ²42 treatment significantly increased protein expressions of p-p38, p-p65 and GFAP, mRNA expression levels of IL-6 and TNF-Î±, and IL-6 and TNF-Î± levels in culture supernatant of U87 cells. SH-SY5Y cells co-cultured with AÎ²42-treated U87 cells showed significantly increased protein expressions of Bax, and exhibited lowered viability following co-culture with 5 Î¼mol/L AÎ²42-treated U87 cells. The isolated mouse astrocytes showed lowered viability following AÎ²42 treatment above 10 Î¼mol/L, but SFN treatment below 5 Î¼mol/L for 24 did not obviously affect the cell viability. The primary neurons co-cultured with AÎ²42-treated mouse astrocytes showed significantly lower cell viability than those co-cultured with the astrocytes treated with AÎ²+SFN or AÎ²+SB203580. SFN attenuates astrocyte-mediated neuron apoptosis by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„ç ”ç©¶ä¸­ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°æŸäº›æœ‰å®³ç‰©è³ªå¦‚AÎ²42çš„æƒ…æ³ä¸‹ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¹«åŠ©æ¸›å°‘ç¥ç¶“ç´°èƒçš„æ­»äº¡ï¼Œé€²è€Œå°æŠ—èˆ‡è€åŒ–ç›¸é—œçš„ç–¾ç—…ï¼Œåƒæ˜¯é˜¿èŒ²ç½•é»˜ç—‡ç­‰ã€‚é€™æ¨£çš„ç™¼ç¾è®“æˆ‘å€‘å°æ–¼å¦‚ä½•é€éé£²é£Ÿä¾†æ”¹å–„ç¥ç¶“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼AÎ²42æ¿€æ´»çš„U87æ˜Ÿç‹€è† è³ªç´°èƒæ‰€å¼•ç™¼çš„SH-SY5Yç¥ç¶“å…ƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶ç¥ç¶“å…ƒå—åˆ°AÎ²42çš„åˆºæ¿€æ™‚ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é€™äº›ç¥ç¶“å…ƒçš„æ­»äº¡ï¼Œä¸¦ä¸”äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…ï¼Œå…·æœ‰é‡è¦çš„æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿé€™äº›è™•ç†å°U87æ˜Ÿç‹€è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬CCK-8æ¸¬è©¦ã€RT-qPCRã€ELISAå’ŒWestern blotç­‰ï¼Œä¾†è©•ä¼°ç´°èƒæ´»æ€§ã€åŸºå› è¡¨é”å’Œè›‹ç™½è³ªé‡‹æ”¾ç­‰è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å°‡SH-SY5Yç¥ç¶“å…ƒèˆ‡è™•ç†éAÎ²42çš„U87æ˜Ÿç‹€è† è³ªç´°èƒå…±åŒåŸ¹é¤Šï¼Œä»¥è§€å¯Ÿé€™äº›ç´°èƒä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œç•¶U87æ˜Ÿç‹€è† è³ªç´°èƒå—åˆ°AÎ²42çš„è™•ç†å¾Œï¼Œç´°èƒæ´»æ€§æœƒå—åˆ°å½±éŸ¿ï¼Œä¸”æœƒå¢åŠ ä¸€äº›ä¿ƒç‚å› å­çš„è¡¨é”ã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŒåŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒé¡¯ç¤ºå‡ºå‡‹äº¡çš„è·¡è±¡ï¼Œä¸”å…¶å­˜æ´»ç‡é™ä½ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨æŸäº›æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†å®ƒä¼¼ä¹èƒ½å¤ æ¸›å°‘AÎ²42å°ç¥ç¶“å…ƒçš„è² é¢å½±éŸ¿ï¼Œé€™å¯èƒ½æ˜¯é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç¥ç¶“ä¿è­·æ–¹é¢å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„ç ”ç©¶ä¸­ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°æŸäº›æœ‰å®³ç‰©è³ªå¦‚AÎ²42çš„æƒ…æ³ä¸‹ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¹«åŠ©æ¸›å°‘ç¥ç¶“ç´°èƒçš„æ­»äº¡ï¼Œé€²è€Œå°æŠ—èˆ‡è€åŒ–ç›¸é—œçš„ç–¾ç—…ï¼Œåƒæ˜¯é˜¿èŒ²ç½•é»˜ç—‡ç­‰ã€‚é€™æ¨£çš„ç™¼ç¾è®“æˆ‘å€‘å°æ–¼å¦‚ä½•é€éé£²é£Ÿä¾†æ”¹å–„ç¥ç¶“å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼AÎ²42æ¿€æ´»çš„U87æ˜Ÿç‹€è† è³ªç´°èƒæ‰€å¼•ç™¼çš„SH-SY5Yç¥ç¶“å…ƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶ç¥ç¶“å…ƒå—åˆ°AÎ²42çš„åˆºæ¿€æ™‚ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›å°‘é€™äº›ç¥ç¶“å…ƒçš„æ­»äº¡ï¼Œä¸¦ä¸”äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…ï¼Œå…·æœ‰é‡è¦çš„æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿé€™äº›è™•ç†å°U87æ˜Ÿç‹€è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬CCK-8æ¸¬è©¦ã€RT-qPCRã€ELISAå’ŒWestern blotç­‰ï¼Œä¾†è©•ä¼°ç´°èƒæ´»æ€§ã€åŸºå› è¡¨é”å’Œè›‹ç™½è³ªé‡‹æ”¾ç­‰è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å°‡SH-SY5Yç¥ç¶“å…ƒèˆ‡è™•ç†éAÎ²42çš„U87æ˜Ÿç‹€è† è³ªç´°èƒå…±åŒåŸ¹é¤Šï¼Œä»¥è§€å¯Ÿé€™äº›ç´°èƒä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œç•¶U87æ˜Ÿç‹€è† è³ªç´°èƒå—åˆ°AÎ²42çš„è™•ç†å¾Œï¼Œç´°èƒæ´»æ€§æœƒå—åˆ°å½±éŸ¿ï¼Œä¸”æœƒå¢åŠ ä¸€äº›ä¿ƒç‚å› å­çš„è¡¨é”ã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŒåŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒé¡¯ç¤ºå‡ºå‡‹äº¡çš„è·¡è±¡ï¼Œä¸”å…¶å­˜æ´»ç‡é™ä½ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨æŸäº›æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†å®ƒä¼¼ä¹èƒ½å¤ æ¸›å°‘AÎ²42å°ç¥ç¶“å…ƒçš„è² é¢å½±éŸ¿ï¼Œé€™å¯èƒ½æ˜¯é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç¥ç¶“ä¿è­·æ–¹é¢å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠNan fang yi ke da xue xue bao = Journal of Southern Medical Universityã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†å—ï¼Ÿæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œé€™å€‹å°æ±è¥¿å¯èƒ½å°æˆ‘å€‘çš„å¤§è…¦å¥åº·æœ‰è‘—æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°ä¸€ç¨®å«åšAÎ²42çš„æœ‰å®³ç‰©è³ªæ™‚ã€‚ç§‘å­¸å®¶å€‘æƒ³çŸ¥é“ï¼Œç•¶ç¥ç¶“ç´°èƒå—åˆ°é€™ç¨®ç‰©è³ªçš„åˆºæ¿€ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦å¹«åŠ©ä¿è­·å®ƒå€‘ä¸å—åˆ°å‚·å®³ã€‚ç‚ºäº†æ‰¾å‡ºç­”æ¡ˆï¼Œç ”ç©¶è€…å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œä½¿ç”¨ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿç´°èƒçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶ç¥ç¶“ç´°èƒæ¥è§¸åˆ°AÎ²42å¾Œï¼Œå®ƒå€‘çš„å­˜æ´»ç‡æœƒä¸‹é™ï¼Œä½†è˜¿è””ç¡«ç´ ä¼¼ä¹èƒ½æ¸›å°‘é€™ç¨®è² é¢å½±éŸ¿ï¼Œå¯èƒ½æ˜¯é€éæŠ‘åˆ¶æŸäº›ä¿ƒç‚å› å­çš„æ–¹å¼ä¾†é”æˆçš„ã€‚é€™è®“æˆ‘å€‘å°æ–¼é£²é£Ÿå¦‚ä½•å½±éŸ¿å¤§è…¦å¥åº·æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç´°èƒï¼Œæ¸›å°‘æ­»äº¡é¢¨éšªã€‚  \n2. é’èŠ±æ¤°èœç­‰é£Ÿç‰©ä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½æˆç‚ºå°æŠ—è€åŒ–ç›¸é—œç–¾ç—…çš„æ½›åœ¨å¹«æ‰‹ã€‚  \n3. äº†è§£é€™äº›æ©Ÿåˆ¶æœ‰åŠ©æ–¼æœªä¾†é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…ã€‚  \nä¸€èµ·ä¾†é—œå¿ƒæˆ‘å€‘çš„é£²é£Ÿï¼Œè®“å¤§è…¦æ›´å¥åº·å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells or neurons, arrows or flow lines to show the experimental process, and a section labeled 'Main Results' highlighting protective effects and changes observed. Use a light-colored background with soft color palettes for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é˜¿èŒ²ç½•é»˜ç—‡ Alzheimer's Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41540706/"
  },
  {
    "id": "41594902",
    "title_en": "Sulforaphane as a Multi-Scale Mechano-Modulator in Cancer: An Integrative Perspective.",
    "pub_date": "2026 Jan",
    "journal": "Biology",
    "abstract_en": "Cancer progression is driven not only by biochemical signals but also by abnormal physical forces within a stiffened tumor microenvironment. This review re-examines the anticancer compound sulforaphane (SFN) through the integrative lens of tumor biomechanics. We propose SFN functions as a \"mechano-modulator,\" whose pleiotropic effects converge to disrupt pro-invasive mechanotransduction. SFN targets key force-sensitive pathways (e.g., YAP/TEAD, Rho/ROCK), destabilizes invasion machinery (cytoskeleton, invadopodia), and promotes tissue-level changes such as extracellular matrix remodeling. While preclinical evidence for this mechano-modulatory role is compelling, this perspective also highlights the critical need for clinical validation and discusses the key translational challenges. By systematically linking SFN's molecular actions to the biophysics of tumor progression, this synthesis provides a novel framework for understanding its efficacy and outlines a rational path for its future development as a mechano-inspired therapeutic.",
    "para1": "é€™ç¯‡ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œé€éèª¿ç¯€è…«ç˜¤çš„æ©Ÿæ¢°ç‰¹æ€§ä¾†å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæ”¹å–„è…«ç˜¤å¾®ç’°å¢ƒçš„ç‰©ç†æ€§è³ªå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡ç ”ç©¶å’Œæ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é€²å±•ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€éå½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ä¾†æ”¹è®Šç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®æ©Ÿæ¢°èª¿ç¯€åŠ‘ï¼Œä¾†å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§å’Œè½‰ç§»éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éï¼Œé‚„åŒ…æ‹¬è…«ç˜¤å¾®ç’°å¢ƒçš„ç‰©ç†ç‰¹æ€§ï¼Œé€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼æ·±å…¥äº†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ã€‚",
    "para3": "åœ¨å¯¦é©—æ–¹æ³•ä¸Šï¼Œé€™ç¯‡æ–‡ç« ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼ï¼Œç³»çµ±æ€§åœ°åˆ†æè˜¿è””ç¡«ç´ çš„åˆ†å­ä½œç”¨èˆ‡è…«ç˜¤é€²å±•çš„ç”Ÿç‰©ç‰©ç†å­¸ä¹‹é–“çš„é—œè¯ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é—œéµçš„åŠ›æ•æ„Ÿé€šè·¯ï¼Œä¸¦ä¸”åˆ†æäº†å®ƒå°è…«ç˜¤ç´°èƒä¾µè¥²æ©Ÿåˆ¶çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç´°èƒéª¨æ¶å’Œä¾µè¥²çªèµ·çš„ç©©å®šæ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„å¼·èª¿äº†è‡¨åºŠé©—è­‰çš„å¿…è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½ä½œç‚ºä¸€ç¨®æ©Ÿæ¢°èª¿ç¯€åŠ‘ï¼Œå°è…«ç˜¤çš„ä¾µè¥²æ€§ç”¢ç”Ÿå¤šé‡å½±éŸ¿ï¼Œé€™äº›å½±éŸ¿å¯èƒ½é€šéæ”¹è®Šç´°èƒçš„æ©Ÿæ¢°æ€§è³ªå’Œé‡å¡‘ç´°èƒå¤–åŸºè³ªä¾†å¯¦ç¾ã€‚é›–ç„¶ç›®å‰çš„å‰è‡¨åºŠè­‰æ“šæ”¯æŒé€™ä¸€è§€é»ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿éœ€è¦é€²ä¸€æ­¥çš„è‡¨åºŠé©—è­‰ï¼Œä»¥ç¢ºä¿é€™äº›ç™¼ç¾èƒ½å¤ è½‰åŒ–ç‚ºæœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™ç¯‡æ–‡ç« æä¾›äº†ä¸€å€‹æ–°çš„æ¡†æ¶ä¾†ç†è§£è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æŒ‡æ˜äº†æ–¹å‘ã€‚",
    "explanation_zh": "é€™ç¯‡ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œé€éèª¿ç¯€è…«ç˜¤çš„æ©Ÿæ¢°ç‰¹æ€§ä¾†å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæ”¹å–„è…«ç˜¤å¾®ç’°å¢ƒçš„ç‰©ç†æ€§è³ªå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡ç ”ç©¶å’Œæ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é€²å±•ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€éå½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ä¾†æ”¹è®Šç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®æ©Ÿæ¢°èª¿ç¯€åŠ‘ï¼Œä¾†å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§å’Œè½‰ç§»éç¨‹ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éï¼Œé‚„åŒ…æ‹¬è…«ç˜¤å¾®ç’°å¢ƒçš„ç‰©ç†ç‰¹æ€§ï¼Œé€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼æ·±å…¥äº†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ã€‚\n\nåœ¨å¯¦é©—æ–¹æ³•ä¸Šï¼Œé€™ç¯‡æ–‡ç« ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼ï¼Œç³»çµ±æ€§åœ°åˆ†æè˜¿è””ç¡«ç´ çš„åˆ†å­ä½œç”¨èˆ‡è…«ç˜¤é€²å±•çš„ç”Ÿç‰©ç‰©ç†å­¸ä¹‹é–“çš„é—œè¯ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é—œéµçš„åŠ›æ•æ„Ÿé€šè·¯ï¼Œä¸¦ä¸”åˆ†æäº†å®ƒå°è…«ç˜¤ç´°èƒä¾µè¥²æ©Ÿåˆ¶çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç´°èƒéª¨æ¶å’Œä¾µè¥²çªèµ·çš„ç©©å®šæ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„å¼·èª¿äº†è‡¨åºŠé©—è­‰çš„å¿…è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½ä½œç‚ºä¸€ç¨®æ©Ÿæ¢°èª¿ç¯€åŠ‘ï¼Œå°è…«ç˜¤çš„ä¾µè¥²æ€§ç”¢ç”Ÿå¤šé‡å½±éŸ¿ï¼Œé€™äº›å½±éŸ¿å¯èƒ½é€šéæ”¹è®Šç´°èƒçš„æ©Ÿæ¢°æ€§è³ªå’Œé‡å¡‘ç´°èƒå¤–åŸºè³ªä¾†å¯¦ç¾ã€‚é›–ç„¶ç›®å‰çš„å‰è‡¨åºŠè­‰æ“šæ”¯æŒé€™ä¸€è§€é»ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿éœ€è¦é€²ä¸€æ­¥çš„è‡¨åºŠé©—è­‰ï¼Œä»¥ç¢ºä¿é€™äº›ç™¼ç¾èƒ½å¤ è½‰åŒ–ç‚ºæœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚é€™ç¯‡æ–‡ç« æä¾›äº†ä¸€å€‹æ–°çš„æ¡†æ¶ä¾†ç†è§£è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æŒ‡æ˜äº†æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiologyã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘æ¯å¤©åƒçš„è˜¿è””å’Œé’èŠ±æ¤°èœè£¡ï¼Œç«Ÿç„¶è—è‘—å°æŠ—ç™Œç—‡çš„ç§˜å¯†æ­¦å™¨ï¼\n\næœ€è¿‘æœ‰ä¸€ç¯‡ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†ï¼Œç™¼ç¾å®ƒä¸åƒ…å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ï¼Œé‚„å¯èƒ½é€éæ”¹è®Šè…«ç˜¤çš„æ©Ÿæ¢°æ€§è³ªä¾†é™ä½ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚é€™è½èµ·ä¾†å¾ˆè¤‡é›œï¼Œä½†ç°¡å–®ä¾†èªªï¼Œå°±æ˜¯è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æˆ‘å€‘çš„èº«é«”æ›´å¥½åœ°å°æŠ—ç™Œç—‡ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼ï¼Œåˆ†æè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ï¼Œä¸¦æ¢è¨å…¶å°è…«ç˜¤ç´°èƒè¡Œç‚ºçš„å½±éŸ¿ã€‚ç ”ç©¶è€…ç™¼ç¾ï¼Œé€™ç¨®æˆåˆ†å¯èƒ½ä½œç‚ºä¸€ç¨®æ©Ÿæ¢°èª¿ç¯€åŠ‘ï¼Œæ”¹è®Šè…«ç˜¤çš„ç‰©ç†ç’°å¢ƒï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚\n\nğŸ”ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰æ½›åŠ›ä½œç‚ºæŠ—ç™Œæˆåˆ†ï¼Œé€éèª¿æ•´è…«ç˜¤çš„ç‰©ç†ç‰¹æ€§ä¾†é™ä½ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚\n2. é€™é …ç ”ç©¶å¼·èª¿äº†æ”¹å–„è…«ç˜¤å¾®ç’°å¢ƒçš„é‡è¦æ€§ï¼Œå¯èƒ½å°ç™Œç—‡é é˜²å’Œæ²»ç™‚æœ‰å¹«åŠ©ã€‚\n3. é›–ç„¶ç›®å‰æœ‰å‰æœŸè­‰æ“šæ”¯æŒé€™äº›è§€é»ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„è‡¨åºŠç ”ç©¶ä¾†é©—è­‰é€™äº›ç™¼ç¾ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç ”ç©¶æˆæœï¼Œç‚ºå¥åº·æ‰“æ‹¼ï¼ğŸ’ªâœ¨",
    "image_prompt": "Create a flat design infographic on a light background that explains the experimental methods and main findings of a study on sulforaphane. Include simple illustrations of broccoli and radish as symbols of sulforaphane, simplified representations of experimental subjects like human cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41594902/"
  },
  {
    "id": "41535692",
    "title_en": "Inhibiting autophagy enhances anti-cancer properties of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Scientific reports",
    "abstract_en": "Bladder cancer (BC) has an extremely low survival rate due to its tendency to metastasize. The antimalarial drug chloroquine (CQ) can inhibit BC progression and invasiveness by targeting basal autophagy. However, the mechanism by which CQ affects BC is not defined. Here, we revealed that although CQ showed an anticancer effect by reducing the migration and proliferation of the analyzed bladder cancer cells, it increased the expression of ICAM-1, a protein whose expression is associated with higher tumorigenic potential. Sulforaphane (SFN), a well-known ICAM-1 inhibitor, significantly contributed to the enhancement of anticancer effect of CQ, through regulation of both AKT/GSK-3Î² and mTOR/ULK pathways, which led to effective inhibition of autophagy, reduced proliferation level or inhibition of migration of the analyzed bladder cells. Moreover, regulation of pathways related to autophagy contributed to the reduction of mitochondrial membrane potential and regulation of ROS level. Nevertheless, the level of influence of CQ and SFN on the anticancer effects strongly depended on the molecular basis of the analyzed bladder cell lines. Our data indicate that although CQ exerts antitumor effects on bladder cancer cells, it should be noted that activation of some pro-tumor pathways may be associated with subsequent disease relapse or treatment resistance.",
    "para1": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®ç”Ÿå­˜ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯ä»¥æŠ‘åˆ¶è†€èƒ±ç™Œçš„é€²å±•ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œèƒ½å¹«åŠ©é†«ç™‚äººå“¡æ›´æœ‰æ•ˆåœ°è¨­è¨ˆæ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦å¯èƒ½æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘ç–¾ç—…å¾©ç™¼çš„é¢¨éšªã€‚é€™äº›ç™¼ç¾ä¹Ÿæé†’æˆ‘å€‘ï¼Œé›–ç„¶æŸäº›è—¥ç‰©å¯èƒ½æœ‰æŠ—ç™Œæ•ˆæœï¼Œä½†ä»éœ€è¬¹æ…è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿç‰©å­¸çš„å½±éŸ¿ï¼Œä»¥é¿å…ä¸å¿…è¦çš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹çš„æŠ—ç™Œæ•ˆæœæ˜¯å¦æœƒä¼´éš¨è‘—æŸäº›ä¿ƒè…«ç˜¤é€”å¾‘çš„æ¿€æ´»ï¼Œé€™å¯èƒ½æœƒå°è‡´ç–¾ç—…å¾©ç™¼æˆ–æ²»ç™‚æŠµæŠ—ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¢å¼·æ°¯å–¹æŠ—ç™Œæ•ˆæœä¸­çš„ä½œç”¨ï¼Œé€™å°æ–¼ç†è§£å…©è€…çš„ç›¸äº’ä½œç”¨åŠå…¶å°è†€èƒ±ç™Œæ²»ç™‚çš„æ½›åœ¨å½±éŸ¿è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„é·ç§»èƒ½åŠ›å’Œå¢æ®–æ°´å¹³ï¼Œä¸¦æª¢æ¸¬ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œå¦‚AKT/GSK-3Î²å’ŒmTOR/ULKé€šè·¯ã€‚é€™äº›é€šè·¯èˆ‡è‡ªå™¬éç¨‹æœ‰é—œï¼Œç ”ç©¶è€…å¸Œæœ›é€šéé€™äº›åˆ†æï¼Œäº†è§£æ°¯å–¹å’Œè˜¿è””ç¡«ç´ å¦‚ä½•å…±åŒä½œç”¨ä¾†æŠ‘åˆ¶è†€èƒ±ç™Œçš„ç™¼å±•ã€‚é€™é …ç ”ç©¶çš„æ–¹å‘æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ï¼Œä»¥æ”¹å–„è†€èƒ±ç™Œæ‚£è€…çš„é å¾Œã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹å°è†€èƒ±ç™Œç´°èƒå…·æœ‰æŠ—è…«ç˜¤æ•ˆæœï¼Œèƒ½æ¸›å°‘ç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹Ÿç™¼ç¾æ°¯å–¹æœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡è…«ç˜¤æ½›èƒ½ç›¸é—œçš„è›‹ç™½è³ªã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œä¸¦é€šéèª¿ç¯€è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾é€™ä¸€é»ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°æŠ—ç™Œæ•ˆæœçš„å½±éŸ¿ç¨‹åº¦å–æ±ºæ–¼æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚éç¨‹ä¸­éœ€è¦è¬¹æ…è€ƒé‡ï¼Œä»¥é¿å…å¯èƒ½çš„æ²»ç™‚æŠµæŠ—æˆ–ç–¾ç—…å¾©ç™¼ã€‚",
    "explanation_zh": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®ç”Ÿå­˜ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯ä»¥æŠ‘åˆ¶è†€èƒ±ç™Œçš„é€²å±•ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œèƒ½å¹«åŠ©é†«ç™‚äººå“¡æ›´æœ‰æ•ˆåœ°è¨­è¨ˆæ²»ç™‚æ–¹æ¡ˆï¼Œä¸¦å¯èƒ½æ”¹å–„æ‚£è€…çš„é å¾Œï¼Œæ¸›å°‘ç–¾ç—…å¾©ç™¼çš„é¢¨éšªã€‚é€™äº›ç™¼ç¾ä¹Ÿæé†’æˆ‘å€‘ï¼Œé›–ç„¶æŸäº›è—¥ç‰©å¯èƒ½æœ‰æŠ—ç™Œæ•ˆæœï¼Œä½†ä»éœ€è¬¹æ…è©•ä¼°å…¶å°è…«ç˜¤ç”Ÿç‰©å­¸çš„å½±éŸ¿ï¼Œä»¥é¿å…ä¸å¿…è¦çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹çš„æŠ—ç™Œæ•ˆæœæ˜¯å¦æœƒä¼´éš¨è‘—æŸäº›ä¿ƒè…«ç˜¤é€”å¾‘çš„æ¿€æ´»ï¼Œé€™å¯èƒ½æœƒå°è‡´ç–¾ç—…å¾©ç™¼æˆ–æ²»ç™‚æŠµæŠ—ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨å¢å¼·æ°¯å–¹æŠ—ç™Œæ•ˆæœä¸­çš„ä½œç”¨ï¼Œé€™å°æ–¼ç†è§£å…©è€…çš„ç›¸äº’ä½œç”¨åŠå…¶å°è†€èƒ±ç™Œæ²»ç™‚çš„æ½›åœ¨å½±éŸ¿è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„é·ç§»èƒ½åŠ›å’Œå¢æ®–æ°´å¹³ï¼Œä¸¦æª¢æ¸¬ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œå¦‚AKT/GSK-3Î²å’ŒmTOR/ULKé€šè·¯ã€‚é€™äº›é€šè·¯èˆ‡è‡ªå™¬éç¨‹æœ‰é—œï¼Œç ”ç©¶è€…å¸Œæœ›é€šéé€™äº›åˆ†æï¼Œäº†è§£æ°¯å–¹å’Œè˜¿è””ç¡«ç´ å¦‚ä½•å…±åŒä½œç”¨ä¾†æŠ‘åˆ¶è†€èƒ±ç™Œçš„ç™¼å±•ã€‚é€™é …ç ”ç©¶çš„æ–¹å‘æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ï¼Œä»¥æ”¹å–„è†€èƒ±ç™Œæ‚£è€…çš„é å¾Œã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹å°è†€èƒ±ç™Œç´°èƒå…·æœ‰æŠ—è…«ç˜¤æ•ˆæœï¼Œèƒ½æ¸›å°‘ç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹Ÿç™¼ç¾æ°¯å–¹æœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡è…«ç˜¤æ½›èƒ½ç›¸é—œçš„è›‹ç™½è³ªã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œä¸¦é€šéèª¿ç¯€è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾é€™ä¸€é»ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ å°æŠ—ç™Œæ•ˆæœçš„å½±éŸ¿ç¨‹åº¦å–æ±ºæ–¼æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚éç¨‹ä¸­éœ€è¦è¬¹æ…è€ƒé‡ï¼Œä»¥é¿å…å¯èƒ½çš„æ²»ç™‚æŠµæŠ—æˆ–ç–¾ç—…å¾©ç™¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠScientific reportsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯ä¸€å€‹è®“è†€èƒ±ç™Œç ”ç©¶è®Šå¾—æ›´æœ‰å¸Œæœ›çš„æˆåˆ†ï¼è†€èƒ±ç™Œæ˜¯ä¸€ç¨®ç”Ÿå­˜ç‡ä¸é«˜çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“æ“´æ•£ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼ŒæŸäº›è—¥ç‰©å¯ä»¥å¹«åŠ©æŠ‘åˆ¶é€™ç¨®ç™Œç—‡çš„é€²å±•ï¼Œé€™å°æ–¼æ”¹å–„æ²»ç™‚æ–¹æ³•éå¸¸é‡è¦ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨ä¸€ç¨®æŠ—ç˜§è—¥ç‰©å«åšæ°¯å–¹ï¼ˆCQï¼‰ï¼Œå®ƒå°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ç‰¹åˆ¥é—œå¿ƒæ°¯å–¹çš„æŠ—ç™Œæ•ˆæœæ˜¯å¦æœƒå¼•ç™¼å…¶ä»–å¯èƒ½ä¿ƒé€²è…«ç˜¤çš„åæ‡‰ï¼ŒåŒæ™‚ä¹Ÿç ”ç©¶äº†è˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­çš„è§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒï¼Œçœ‹çœ‹æ°¯å–¹å’Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å®ƒå€‘çš„å¢æ®–å’Œé·ç§»èƒ½åŠ›ã€‚ä»–å€‘ç™¼ç¾æ°¯å–¹ç¢ºå¯¦èƒ½æ¸›å°‘ç™Œç´°èƒçš„å¢é•·ï¼Œä½†ä¹Ÿæœƒå¢åŠ ä¸€ç¨®èˆ‡è…«ç˜¤ç›¸é—œçš„è›‹ç™½è³ªçš„è¡¨é”ã€‚å¹¸å¥½ï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶é€™å€‹è›‹ç™½è³ªï¼Œé€²ä¸€æ­¥å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n1. æ°¯å–¹å°è†€èƒ±ç™Œç´°èƒæœ‰æŠ—è…«ç˜¤æ•ˆæœã€‚  \n2. è˜¿è””ç¡«ç´ èƒ½å¢å¼·æ°¯å–¹çš„æ•ˆæœï¼Œå¹«åŠ©æŠ‘åˆ¶è…«ç˜¤ã€‚  \n3. æ²»ç™‚éç¨‹ä¸­éœ€è¦è¬¹æ…è€ƒé‡ï¼Œä»¥é¿å…ç™Œç—‡å¾©ç™¼ã€‚",
    "image_prompt": "Create a flat design infographic on the effects of chloroquine and sulforaphane on bladder cancer cells. Include simplified illustrations of broccoli or sulforaphane, and simplified representations of cells. Use arrows or flow lines to depict the experimental steps. Add a section highlighting key results, such as protective effects or changes in cell behavior. Use a light background with soft colors, making it easy to understand for a general audience.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è†€èƒ±ç™Œ Bladder Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41535692/"
  },
  {
    "id": "41543290",
    "title_en": "Elucidation of Sulforaphane-Mediated Effects on the Cellular Human Metabolome Using Metabolic Profiling.",
    "pub_date": "2026 Jan",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from glucoraphanin, which occurs in broccoli. Several human health-promoting effects are attributed to the consumption of cruciferous vegetables or food supplements containing SFN. Its described cancer-preventive, chemoprotective, and antioxidant properties made SFN an increasingly important research topic. The antioxidant properties have previously been connected to stimulation of the Nuclear factor erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway. However, the global effects of SFN on the primary metabolic pathways have yet to be fully unraveled. Therefore metabolic profiling was used to elucidate the effects of SFN on the cellular metabolome. For this purpose, human hepatoblastoma cells (HepG2) were incubated with SFN and the changes of primary metabolite levels were determined by targeted hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC-MS/MS) analysis. Metabolic profiling revealed that SFN affects the tricarboxylic acid cycle, the urea cycle and their related amino acids. Furthermore, effects on glycolysis, pentose phosphate pathway and glutathione (GSH) levels were observed. This profound impact on nearly all primary metabolic pathways indicates a high bioactive potential of this natural compound. Especially elevated GSH levels underline the commonly described antioxidant potential of SFN.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰ç›Šï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²æŸäº›ç–¾ç—…æ–¹é¢ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨åå­—èŠ±ç§‘è”¬èœæˆ–å«æœ‰è˜¿è””ç¡«ç´ çš„é£Ÿå“è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½ç™Œç—‡é¢¨éšªï¼Œä¸¦æä¾›æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒçš„æ•ˆæœã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºç ”ç©¶çš„ç†±é»ï¼Œå°¤å…¶æ˜¯åœ¨äº†è§£å…¶å¦‚ä½•å½±éŸ¿èº«é«”çš„ä»£è¬éç¨‹æ–¹é¢ï¼Œé€™å°æ–¼ç–¾ç—…çš„é é˜²å’Œå¥åº·ä¿ƒé€²éƒ½å¯èƒ½æœ‰é‡è¦çš„å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚é›–ç„¶ä¹‹å‰çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä¸¦èˆ‡ä¸€äº›ç´°èƒä¿¡è™Ÿå‚³å°é€”å¾‘æœ‰é—œï¼Œä½†å°æ–¼å®ƒåœ¨ä¸»è¦ä»£è¬é€”å¾‘ä¸Šçš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéä»£è¬å‰–æä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒå…§ä»£è¬ç‰©çš„å½±éŸ¿ï¼Œé€™å°‡æœ‰åŠ©æ–¼æ­ç¤ºå…¶æ½›åœ¨çš„ç”Ÿç‰©æ´»æ€§ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç ”ç©¶ä»£è¬çš„ç´°èƒæ¨¡å‹ã€‚ç ”ç©¶åœ˜éšŠå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ å…±åŒåŸ¹é¤Šï¼Œç„¶å¾Œåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§ç›¸äº’ä½œç”¨æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•èƒ½å¤ å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œä¸¦æ­ç¤ºå…¶æ½›åœ¨çš„ç”Ÿç‰©æ´»æ€§ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘æœ‰é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰é«˜ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„ç‰¹æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ï¼Œä½†ä»éœ€é€²ä¸€æ­¥æ¢ç´¢å…¶å…·é«”çš„å¥åº·æ•ˆç›Šã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰ç›Šï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²æŸäº›ç–¾ç—…æ–¹é¢ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨åå­—èŠ±ç§‘è”¬èœæˆ–å«æœ‰è˜¿è””ç¡«ç´ çš„é£Ÿå“è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½ç™Œç—‡é¢¨éšªï¼Œä¸¦æä¾›æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒçš„æ•ˆæœã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•ä½¿å¾—è˜¿è””ç¡«ç´ æˆç‚ºç ”ç©¶çš„ç†±é»ï¼Œå°¤å…¶æ˜¯åœ¨äº†è§£å…¶å¦‚ä½•å½±éŸ¿èº«é«”çš„ä»£è¬éç¨‹æ–¹é¢ï¼Œé€™å°æ–¼ç–¾ç—…çš„é é˜²å’Œå¥åº·ä¿ƒé€²éƒ½å¯èƒ½æœ‰é‡è¦çš„å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚é›–ç„¶ä¹‹å‰çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä¸¦èˆ‡ä¸€äº›ç´°èƒä¿¡è™Ÿå‚³å°é€”å¾‘æœ‰é—œï¼Œä½†å°æ–¼å®ƒåœ¨ä¸»è¦ä»£è¬é€”å¾‘ä¸Šçš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéä»£è¬å‰–æä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒå…§ä»£è¬ç‰©çš„å½±éŸ¿ï¼Œé€™å°‡æœ‰åŠ©æ–¼æ­ç¤ºå…¶æ½›åœ¨çš„ç”Ÿç‰©æ´»æ€§ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç ”ç©¶ä»£è¬çš„ç´°èƒæ¨¡å‹ã€‚ç ”ç©¶åœ˜éšŠå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ å…±åŒåŸ¹é¤Šï¼Œç„¶å¾Œåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§ç›¸äº’ä½œç”¨æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•èƒ½å¤ å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œä¸¦æ­ç¤ºå…¶æ½›åœ¨çš„ç”Ÿç‰©æ´»æ€§ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘æœ‰é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰é«˜ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„ç‰¹æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ï¼Œä½†ä»éœ€é€²ä¸€æ­¥æ¢ç´¢å…¶å…·é«”çš„å¥åº·æ•ˆç›Šã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†å—ï¼Ÿæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œé€™å€‹å°å°çš„åŒ–åˆç‰©å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®äººé¡è‚ç™Œç´°èƒä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å®ƒå€‘èˆ‡è˜¿è””ç¡«ç´ ä¸€èµ·åŸ¹é¤Šï¼Œç„¶å¾Œåˆ†æç´°èƒå…§çš„ä»£è¬ç‰©è®ŠåŒ–ã€‚é€™æ¨£çš„å¯¦é©—èƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘é«”å…§çš„åŒ–å­¸éç¨‹ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹é‡è¦çš„ä»£è¬é€”å¾‘æœ‰é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬èƒ½é‡ç”¢ç”Ÿå’ŒæŠ—æ°§åŒ–èƒ½åŠ›ã€‚ç‰¹åˆ¥æ˜¯ï¼Œå®ƒèƒ½æé«˜ç´°èƒå…§çš„è°·èƒ±ç”˜è‚½æ°´å¹³ï¼Œé€™æ˜¯ä¸€ç¨®å¼·æ•ˆçš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¹«åŠ©ä¿è­·æˆ‘å€‘çš„ç´°èƒä¸å—å‚·å®³ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼ä»¥ä¸‹æ˜¯å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é™ä½ç™Œç—‡é¢¨éšªã€‚\n2. å®ƒå¯ä»¥æå‡ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. é€²ä¸€æ­¥ç ”ç©¶å°‡æ­ç¤ºæ›´å¤šå¥åº·ç›Šè™•ï¼\n\nå¿«ä¾†åˆ†äº«é€™äº›å¥åº·å°çŸ¥è­˜å§ï¼",
    "image_prompt": "Create an informative illustration that explains the experiment and main results of a study on sulforaphane. The style should be flat design with a white or light background and soft colors. Include symbols representing broccoli or sulforaphane, a simplified illustration of human or animal cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‚ç™Œ Hepatocellular Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41543290/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰æœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”ç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚é€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ï¼Œå› ç‚ºç›®å‰çš„æ²»ç™‚æ–¹æ³•ä»ç„¶å­˜åœ¨è¨±å¤šæŒ‘æˆ°å’Œé™åˆ¶ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©ä¾†æºçš„åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶OSCCçš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œéå¸¸é‡è¦ï¼Œå› ç‚ºå£è…”ç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹ä¸”å…·æœ‰æŒ‘æˆ°æ€§çš„ç™Œç—‡ï¼Œäº†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œè‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†OSCCç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦è§€å¯ŸSFN-Cyså°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬è©¦SFN-Cyså°ç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„å½±éŸ¿ä»¥åŠä¿ƒé€²ç´°èƒå‡‹äº¡çš„èƒ½åŠ›ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦æª¢æ¸¬äº†ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼ˆå¦‚c-Jun N-terminal kinaseï¼ŒJNKï¼‰åœ¨é€™äº›éç¨‹ä¸­çš„ä½œç”¨ï¼Œä»¥äº†è§£SFN-Cysçš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°OSCCç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼ŒSFN-Cysçš„è™•ç†æœƒä¸‹èª¿å‡‹äº¡æŠ‘åˆ¶å› å­ï¼Œä¸¦æ¿€æ´»caspaseç´šè¯åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯ä¿ƒé€²ç´°èƒå‡‹äº¡çš„é‡è¦æ­¥é©Ÿã€‚æ­¤å¤–ï¼ŒSFN-Cysè™•ç†çš„OSCCç´°èƒåœ¨ä½¿ç”¨ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘å¾Œï¼Œå…¶caspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé¡¯ç¤ºJNKé€šè·¯åœ¨SFN-Cysçš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†å¯èƒ½çš„é€”å¾‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰æœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”ç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚é€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…å’Œé†«ç™‚å°ˆæ¥­äººå“¡ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ï¼Œå› ç‚ºç›®å‰çš„æ²»ç™‚æ–¹æ³•ä»ç„¶å­˜åœ¨è¨±å¤šæŒ‘æˆ°å’Œé™åˆ¶ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©ä¾†æºçš„åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶OSCCçš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œéå¸¸é‡è¦ï¼Œå› ç‚ºå£è…”ç™Œæ˜¯ä¸€ç¨®å¸¸è¦‹ä¸”å…·æœ‰æŒ‘æˆ°æ€§çš„ç™Œç—‡ï¼Œäº†è§£å…¶æ½›åœ¨çš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œè‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†OSCCç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦è§€å¯ŸSFN-Cyså°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬è©¦SFN-Cyså°ç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„å½±éŸ¿ä»¥åŠä¿ƒé€²ç´°èƒå‡‹äº¡çš„èƒ½åŠ›ã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡å‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦æª¢æ¸¬äº†ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼ˆå¦‚c-Jun N-terminal kinaseï¼ŒJNKï¼‰åœ¨é€™äº›éç¨‹ä¸­çš„ä½œç”¨ï¼Œä»¥äº†è§£SFN-Cysçš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆèª˜å°OSCCç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²å‡‹äº¡äº‹ä»¶çš„ç™¼ç”Ÿã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼ŒSFN-Cysçš„è™•ç†æœƒä¸‹èª¿å‡‹äº¡æŠ‘åˆ¶å› å­ï¼Œä¸¦æ¿€æ´»caspaseç´šè¯åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯ä¿ƒé€²ç´°èƒå‡‹äº¡çš„é‡è¦æ­¥é©Ÿã€‚æ­¤å¤–ï¼ŒSFN-Cysè™•ç†çš„OSCCç´°èƒåœ¨ä½¿ç”¨ç‰¹å®šçš„JNKæŠ‘åˆ¶åŠ‘å¾Œï¼Œå…¶caspaseçš„æ´»åŒ–å—åˆ°å½±éŸ¿ï¼Œé¡¯ç¤ºJNKé€šè·¯åœ¨SFN-Cysçš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºåˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”æƒ¡æ€§è…«ç˜¤æä¾›äº†å¯èƒ½çš„é€”å¾‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿä¸€äº›æˆ‘å€‘å¹³å¸¸åƒçš„è”¬èœï¼Œå¯èƒ½å°å¥åº·æœ‰è‘—æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œå°å£è…”ç™Œçš„ç´°èƒç«Ÿç„¶æœ‰æŠ‘åˆ¶ä½œç”¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯åœ¨æ¢è¨SFN-Cyså¦‚ä½•å½±éŸ¿å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰ã€‚ç ”ç©¶è€…å€‘ç”¨é€™ç¨®åŒ–åˆç‰©ä¾†çœ‹çœ‹å®ƒèƒ½å¦æ¸›ç·©ç™Œç´°èƒçš„å¢é•·ï¼Œé‚„æ·±å…¥äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘è§€å¯Ÿäº†SFN-Cyså°ç™Œç´°èƒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç´°èƒçš„ç”Ÿæ­»å¾ªç’°å’Œå‡‹äº¡ï¼ˆç´°èƒè‡ªæ®ºï¼‰çš„éç¨‹ã€‚\n\nçµæœé¡¯ç¤ºï¼ŒSFN-Cysèƒ½æœ‰æ•ˆåœ°èª˜å°OSCCç´°èƒæ­»äº¡ï¼Œä¸¦é˜»æ­¢å®ƒå€‘çš„å¢é•·ã€‚æ­¤å¤–ï¼Œé€™å€‹åŒ–åˆç‰©é‚„èƒ½å•Ÿå‹•ä¸€äº›èˆ‡ç´°èƒå‡‹äº¡æœ‰é—œçš„ä¿¡è™Ÿé€šè·¯ï¼Œé€™è®“ç§‘å­¸å®¶å€‘çœ‹åˆ°äº†æœªä¾†å¯èƒ½çš„æ²»ç™‚æ–¹å‘ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸å¯èƒ½æˆç‚ºå£è…”ç™Œæ²»ç™‚çš„æ–°é¸æ“‡ã€‚\n2. å®ƒèƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ä¸¦æŠ‘åˆ¶å¢é•·ã€‚\n3. äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶å°æœªä¾†æ²»ç™‚è‡³é—œé‡è¦ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experimental method and main findings of a study on Sulforaphane-Cysteine (SFN-Cys) and oral squamous cell carcinoma (OSCC). Include simple icons representing broccoli or sulfur compounds, simplified representations of cells, and arrows or flow lines indicating the experimental steps. Add a section highlighting the main results, such as protective effects and changes observed in the cancer cells.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2026 Jan",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±æ–¼é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ï¼ˆå¦‚å»æ°§é†‹é…¸ï¼Œç°¡ç¨±DONï¼‰æ‰€å¼•èµ·çš„è…¸é“æå‚·ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰ä¿è­·è…¸é“çš„æ½›åŠ›ï¼Œé€™å°æ–¼é é˜²ç”±DONå¼•èµ·çš„å¥åº·å•é¡Œå…·æœ‰é‡è¦æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·è…¸é“å¥åº·ï¼Œæ¸›å°‘ç›¸é—œç–¾ç—…çš„é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å»æ°§é†‹é…¸å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±DONå¼•èµ·çš„è…¸é“æ¯’æ€§ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„å¥åº·ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ä½¿ç”¨äº†è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œé«”å¤–å¯¦é©—ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡åˆ†æå’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºå’Œä»£è¬çµ„å­¸ç­‰æ–¹æ³•é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•ç”±å»æ°§é†‹é…¸å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç´¯ç©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéå¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œä¸¦ä¸”ATPçš„è£œå……é€²ä¸€æ­¥å¢å¼·äº†é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä¾†æ¸›è¼•è…¸é“æå‚·ï¼Œæœªä¾†å€¼å¾—é€²ä¸€æ­¥æ¢è¨å…¶èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç”±æ–¼é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ï¼ˆå¦‚å»æ°§é†‹é…¸ï¼Œç°¡ç¨±DONï¼‰æ‰€å¼•èµ·çš„è…¸é“æå‚·ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶æ™®éï¼Œå°äººé¡å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰ä¿è­·è…¸é“çš„æ½›åŠ›ï¼Œé€™å°æ–¼é é˜²ç”±DONå¼•èµ·çš„å¥åº·å•é¡Œå…·æœ‰é‡è¦æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·è…¸é“å¥åº·ï¼Œæ¸›å°‘ç›¸é—œç–¾ç—…çš„é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å»æ°§é†‹é…¸å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±DONå¼•èµ·çš„è…¸é“æ¯’æ€§ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„å¥åº·ç›Šè™•ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ä½¿ç”¨äº†è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œé«”å¤–å¯¦é©—ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡åˆ†æå’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºå’Œä»£è¬çµ„å­¸ç­‰æ–¹æ³•é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•ç”±å»æ°§é†‹é…¸å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç´¯ç©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéå¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œä¸¦ä¸”ATPçš„è£œå……é€²ä¸€æ­¥å¢å¼·äº†é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éATP6AP1ä»‹å°çš„æº¶é…¶é«”é…¸åŒ–ä¾†æ¸›è¼•è…¸é“æå‚·ï¼Œæœªä¾†å€¼å¾—é€²ä¸€æ­¥æ¢è¨å…¶èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“å¥åº·å¯èƒ½è·Ÿä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„æˆåˆ†æœ‰é—œï¼Œé€™å€‹æˆåˆ†å«ã€Œè˜¿è””ç¡«ç´ ã€ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ä¸€ç¨®å¸¸è¦‹çš„é£Ÿç‰©æ¯’ç´ â€”â€”å»æ°§é†‹é…¸ï¼ˆDONï¼‰æœ‰å¹«åŠ©ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­å¾ˆå¸¸è¦‹ï¼Œå°å¥åº·æœ‰æ½›åœ¨é¢¨éšªã€‚\n\nç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ å’Œç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•æ¸›è¼•ç”±DONå¼•èµ·çš„è…¸é“æå‚·ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„è…¸é“çš„çµæ§‹ï¼Œé‚„èƒ½æ¸›å°‘ç´°èƒçš„æ­»äº¡å’Œæ°§åŒ–å£“åŠ›ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨è…¸é“å¥åº·ä¸­çš„æ½›åŠ›ã€‚\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ¸›å°‘ç”±å»æ°§é†‹é…¸å¼•èµ·çš„è…¸é“æå‚·ã€‚\n2. å®ƒå¯ä»¥æ”¹å–„è…¸é“çš„çµæ§‹å’Œæ°§åŒ–é‚„åŸå¹³è¡¡ã€‚\n3. è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨å¯èƒ½èˆ‡å¢å¼·ç´°èƒå…§çš„é…¸åŒ–æœ‰é—œã€‚\n\né€™äº›çµæœè®“æˆ‘å€‘å°æœªä¾†çš„è…¸é“å¥åº·ç ”ç©¶å……æ»¿å¸Œæœ›ï¼",
    "image_prompt": "Create an infographic illustrating the experimental methods and key findings from a study on the protective effects of sulforaphane (from broccoli) against a common food toxin called deoxynivalenol (DON). Include simplified icons representing broccoli, mice, and cells. Use arrows or flow lines to show the steps of the experiment. Highlight a section labeled 'Key Findings' with simple statements about the protective effects and improvements observed in the study. Use a flat design style with a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›å¢å¼·é£²é£Ÿå¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´é‡è¦–é’èŠ±æ¤°èœåŠå…¶è¡ç”Ÿç”¢å“åœ¨æ—¥å¸¸é£²é£Ÿä¸­çš„é‡è¦æ€§ï¼Œä¸¦é¼“å‹µé€²ä¸€æ­¥çš„ç ”ç©¶ä¾†æ¢ç´¢å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé‚„å¯èƒ½å°åŠŸèƒ½æ€§é£Ÿå“çš„é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦å°å…¶æ–½åŠ äº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†å„ç¨®æ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶è‘¡è„ç³–è‹·çš„å«é‡å’Œå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„ä¿ç•™æƒ…æ³ã€‚é€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨å„ªåŒ–é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œä¸¦æ¢ç´¢å…¶åœ¨åŠŸèƒ½æ€§é£Ÿå“ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†ç›¸å°è¼ƒé«˜çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆï¼Œç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†æœ‰å¸Œæœ›çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›å¢å¼·é£²é£Ÿå¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´é‡è¦–é’èŠ±æ¤°èœåŠå…¶è¡ç”Ÿç”¢å“åœ¨æ—¥å¸¸é£²é£Ÿä¸­çš„é‡è¦æ€§ï¼Œä¸¦é¼“å‹µé€²ä¸€æ­¥çš„ç ”ç©¶ä¾†æ¢ç´¢å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé‚„å¯èƒ½å°åŠŸèƒ½æ€§é£Ÿå“çš„é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦å°å…¶æ–½åŠ äº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†å„ç¨®æ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶è‘¡è„ç³–è‹·çš„å«é‡å’Œå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„ä¿ç•™æƒ…æ³ã€‚é€™äº›æ–¹æ³•çš„çµåˆæ—¨åœ¨å„ªåŒ–é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œä¸¦æ¢ç´¢å…¶åœ¨åŠŸèƒ½æ€§é£Ÿå“ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†ç›¸å°è¼ƒé«˜çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆï¼Œç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†æœ‰å¸Œæœ›çš„æ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½æ˜¯ä¸€ç¨®å¥åº·çš„è¶…ç´šé£Ÿç‰©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼é’èŠ±æ¤°èœèŠ½ï¼Œç™¼ç¾äº†ä¸€äº›ä»¤äººé©šå–œçš„çµæœã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚ \n\nä»–å€‘åœ¨å¯¦é©—ä¸­ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ–½åŠ äº†ç‰¹æ®Šçš„å£“åŠ›è™•ç†ï¼Œè®“é€™äº›èŠ½åœ¨å››å¤©å…§ç”Ÿé•·ï¼Œç„¶å¾Œé€²è¡Œå„ç¨®æ¸¬è©¦ã€‚ç ”ç©¶è€…é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œé€éé€™äº›è™•ç†ï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†æœ‰äº†é¡¯è‘—æå‡ï¼\n\nä»¥ä¸‹æ˜¯å¹¾å€‹é‡è¦çš„ç™¼ç¾ï¼š\n1. è”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥èƒ½æœ‰æ•ˆä¿ç•™è˜¿è””ç¡«ç´ ï¼Œä¸¦å±•ç¾è‰¯å¥½çš„å“è³ªã€‚\n3. è˜¿è””ç¡«ç´ å°æŸäº›ç´°èŒæœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚\n\né€™äº›çµæœä¸åƒ…è®“æˆ‘å€‘é‡æ–°èªè­˜é’èŠ±æ¤°èœï¼Œä¹Ÿç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“é–‹ç™¼æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main findings of a study on broccoli sprouts. Include simplified illustrations of broccoli or a symbol for sulforaphane. Show experimental subjects like people or cells in a simplified manner. Use arrows or flow lines to indicate the steps of the experiment. Include a section that clearly states the main results, such as protective effects or changes observed in the study. Use a white or light-colored background with soft colors to keep it informative and visually appealing.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›çš„å¢åŠ ï¼Œå‘¼å¸é“ç–¾ç—…çš„ç™¼ç”Ÿç‡é€æ¼¸ä¸Šå‡ï¼Œå› æ­¤æ¢ç´¢é€™äº›å¤©ç„¶ç‰©è³ªçš„æ•ˆæœï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ä½œç”¨ä¸Šã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é€™äº›æˆåˆ†çš„ç”Ÿç‰©æ´»æ€§ï¼Œä¹Ÿå¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨çš„GO-PEGå¥ˆç±³ç²’å­æ˜¯ç”±çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶ç´°èƒæ¯’æ€§ã€‚å¯¦é©—ä¸­ä¹ŸåŒæ™‚è©•ä¼°äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†æ¸¬é‡ç´°èƒå­˜æ´»ç‡ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£é€™äº›ç‰©è³ªçš„ç”Ÿç‰©æ•ˆæ‡‰ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚é›–ç„¶é€™äº›ç™¼ç¾é¡¯ç¤ºå‡ºé€™äº›ç‰©è³ªçš„æ­£é¢æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›çš„å¢åŠ ï¼Œå‘¼å¸é“ç–¾ç—…çš„ç™¼ç”Ÿç‡é€æ¼¸ä¸Šå‡ï¼Œå› æ­¤æ¢ç´¢é€™äº›å¤©ç„¶ç‰©è³ªçš„æ•ˆæœï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ä½œç”¨ä¸Šã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£é€™äº›æˆåˆ†çš„ç”Ÿç‰©æ´»æ€§ï¼Œä¹Ÿå¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨çš„GO-PEGå¥ˆç±³ç²’å­æ˜¯ç”±çŸ³å¢¨è£½æˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶ç´°èƒæ¯’æ€§ã€‚å¯¦é©—ä¸­ä¹ŸåŒæ™‚è©•ä¼°äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„å½±éŸ¿ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†æ¸¬é‡ç´°èƒå­˜æ´»ç‡ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£é€™äº›ç‰©è³ªçš„ç”Ÿç‰©æ•ˆæ‡‰ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚é›–ç„¶é€™äº›ç™¼ç¾é¡¯ç¤ºå‡ºé€™äº›ç‰©è³ªçš„æ­£é¢æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªå¥½åƒï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œæ¢è¨äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°å‘¼å¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“é€™äº›å¤©ç„¶æˆåˆ†å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„ç´°èƒï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚  \n  \nä»–å€‘å¾é»‘è˜¿è””æ±ä¸­æå–è˜¿è””ç¡«ç´ ï¼Œä¸¦é€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼Œçœ‹çœ‹é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½ä¸€ç¨®å«IL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œé‚„èƒ½æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œé€™äº›éƒ½æ˜¯å°æŠ—ç‚ç—‡å’Œä¿è­·ç´°èƒçš„é‡è¦å› ç´ ï¼  \n  \né€™é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°å¤©ç„¶é£Ÿæåœ¨å¥åº·æ–¹é¢çš„æ½›åŠ›ï¼Œé›–ç„¶é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…·é«”çš„æ•ˆæœï¼Œä½†é€™äº›ç™¼ç¾çœŸçš„æ˜¯å€¼å¾—é—œæ³¨çš„ï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼å‘¼å¸é“å¥åº·ã€‚  \n2. é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚  \n3. æœªä¾†å¯èƒ½æˆç‚ºå¥åº·ä¿ƒé€²çš„æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of a study on the effects of daikon sulforaphane and black radish juice on bronchial epithelial cells. Include simplified icons representing daikon or broccoli, human or cell figures as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as protective effects and changes in inflammation markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰å’Œæ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„æ²»ç™‚ä¸Šã€‚é€™äº›ç–¾ç—…ç›®å‰æ²’æœ‰æ ¹æ²»çš„æ–¹æ³•ï¼Œç¾æœ‰çš„è—¥ç‰©é›–ç„¶èƒ½æ§åˆ¶ç—‡ç‹€ï¼Œä½†ä¹Ÿä¼´éš¨è‘—è¨±å¤šåš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„ç™‚æ³•ï¼Œé¡¯å¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å…©ç¨®å¤©ç„¶åŒ–åˆç‰©â€”â€”è¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›åŒ–åˆç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œå¾è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„æŠ—ç‚æ½›åŠ›ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®ä»¥çµè…¸æŒçºŒæ€§ç‚ç—‡ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œæ‚£è€…é€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ã€‚ç”±æ–¼ç›®å‰çš„æ²»ç™‚æ–¹æ³•å­˜åœ¨å‰¯ä½œç”¨ï¼Œå› æ­¤ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶æ‰¾åˆ°æ›´å®‰å…¨çš„æ›¿ä»£ç™‚æ³•ï¼Œä¾†å¹«åŠ©æ§åˆ¶é€™ç¨®ç–¾ç—…çš„ç‚ç—‡åæ‡‰ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›çµè…¸é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚ç‚ºäº†æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒï¼Œç ”ç©¶è€…å°‡é€™äº›é¡å™¨å®˜åœ¨2%çš„æ°§æ°£æ¿ƒåº¦ä¸‹åŸ¹é¤Šã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ å°æ–¼èˆ‡ç‚ç—‡ç›¸é—œçš„ç´°èƒä¿¡è™Ÿé€šè·¯çš„å½±éŸ¿ï¼Œä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†æ¸¬é‡ç‚ç—‡å› å­çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚åæ‡‰ç›¸é—œçš„è½‰éŒ„å› å­ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç‚ç—‡çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ä¹‹ä¸€ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸é¡å™¨å®˜ä½œç‚ºè—¥ç‰©æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰å’Œæ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„æ²»ç™‚ä¸Šã€‚é€™äº›ç–¾ç—…ç›®å‰æ²’æœ‰æ ¹æ²»çš„æ–¹æ³•ï¼Œç¾æœ‰çš„è—¥ç‰©é›–ç„¶èƒ½æ§åˆ¶ç—‡ç‹€ï¼Œä½†ä¹Ÿä¼´éš¨è‘—è¨±å¤šåš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„ç™‚æ³•ï¼Œé¡¯å¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å…©ç¨®å¤©ç„¶åŒ–åˆç‰©â€”â€”è¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›åŒ–åˆç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œå¾è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„æŠ—ç‚æ½›åŠ›ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®ä»¥çµè…¸æŒçºŒæ€§ç‚ç—‡ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œæ‚£è€…é€šå¸¸åœ¨é’å°‘å¹´æ™šæœŸåˆ°ä¸‰åå¤šæ­²ä¹‹é–“è¢«è¨ºæ–·ã€‚ç”±æ–¼ç›®å‰çš„æ²»ç™‚æ–¹æ³•å­˜åœ¨å‰¯ä½œç”¨ï¼Œå› æ­¤ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶æ‰¾åˆ°æ›´å®‰å…¨çš„æ›¿ä»£ç™‚æ³•ï¼Œä¾†å¹«åŠ©æ§åˆ¶é€™ç¨®ç–¾ç—…çš„ç‚ç—‡åæ‡‰ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›çµè…¸é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚ç‚ºäº†æ›´å¥½åœ°æ¨¡æ“¬çµè…¸éš±çª©ä¸­çš„ä½æ°§ç’°å¢ƒï¼Œç ”ç©¶è€…å°‡é€™äº›é¡å™¨å®˜åœ¨2%çš„æ°§æ°£æ¿ƒåº¦ä¸‹åŸ¹é¤Šã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°äº†è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ å°æ–¼èˆ‡ç‚ç—‡ç›¸é—œçš„ç´°èƒä¿¡è™Ÿé€šè·¯çš„å½±éŸ¿ï¼Œä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†æ¸¬é‡ç‚ç—‡å› å­çš„è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚åæ‡‰ç›¸é—œçš„è½‰éŒ„å› å­ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBä¿ƒé€²çš„æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç‚ç—‡çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ä¹‹ä¸€ã€‚é€™äº›çµæœé©—è­‰äº†çµè…¸é¡å™¨å®˜ä½œç‚ºè—¥ç‰©æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶é£Ÿæå¯èƒ½å°è…¸é“å¥åº·å¤§æœ‰å¹«åŠ©ï¼é€™ç¯‡ç ”ç©¶å°ˆæ³¨æ–¼æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®è®“äººä¸èˆ’æœçš„è…¸é“ç–¾ç—…ï¼Œç¾åœ¨çš„æ²»ç™‚æ–¹æ³•é›–ç„¶èƒ½æ§åˆ¶ç—‡ç‹€ï¼Œä½†å‰¯ä½œç”¨å»è®“äººæ“”å¿ƒã€‚é€™æ¬¡ï¼Œç ”ç©¶è€…å€‘æ¢è¨äº†è¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒå€‘æ˜¯å¦èƒ½å¹«åŠ©æ¸›å°‘è…¸é“çš„ç‚ç—‡ã€‚  \n  \nä»–å€‘ç”¨ä¾†è‡ªå¥åº·äººå’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ç´°èƒé€²è¡Œå¯¦é©—ï¼Œæ¨¡æ“¬çœŸå¯¦çš„è…¸é“ç’°å¢ƒï¼Œä¸¦åœ¨ä½æ°§çš„æ¢ä»¶ä¸‹åŸ¹é¤Šé€™äº›ç´°èƒã€‚æ¥è‘—ï¼Œä»–å€‘è§€å¯Ÿè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ å°ç‚ç—‡ç›¸é—œçš„ç´°èƒä¿¡è™Ÿçš„å½±éŸ¿ã€‚  \n  \nçµæœç™¼ç¾ï¼Œé€™å…©ç¨®å¤©ç„¶åŒ–åˆç‰©èƒ½é™ä½ç‚ç—‡æ¨™è¨˜ï¼Œä¸¦ä¿ƒé€²ä¸€ç¨®å«NRF2çš„å› å­æ´»æ€§ï¼Œé€™æœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—ç‚åæ‡‰ã€‚æ­¤å¤–ï¼Œå®ƒå€‘é‚„èƒ½èª¿ç¯€æŠ—èŒè‚½çš„è¡¨é”ï¼Œé€™åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­è¢«è¦–ç‚ºé‡è¦çš„ç”Ÿç‰©æ¨™è¨˜ã€‚  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“ç‚ç—‡ã€‚  \n2. é€™äº›åŒ–åˆç‰©å°è…¸é“å¥åº·çš„æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚  \n3. ç ”ç©¶æä¾›äº†æ–°çš„æ€è·¯ï¼Œå°‹æ‰¾æ›´å®‰å…¨çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚é¸é …ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of the study on sulforaphane and cinnamic acid. Use a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, and arrows or flow lines to indicate experimental steps. Include a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰å¤šç¨®å¥½è™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¯èƒ½ç„¡æ³•å……åˆ†åˆ©ç”¨å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®è½‰æ›çš„æ©Ÿåˆ¶ä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·è½‰æ›ç‡ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ çš„å¥åº·æ•ˆç›Šå—åˆ°å…¶è½‰æ›æ•ˆç‡çš„å½±éŸ¿ï¼Œå› æ­¤äº†è§£é€™ä¸€éç¨‹å°æ–¼æœªä¾†çš„æ‡‰ç”¨å’Œç ”ç©¶è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æå‡ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æå…¶ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸çš„ä»£è¬è®ŠåŒ–ã€‚é€éè½‰éŒ„çµ„åˆ†æï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£é€™äº›èŒæ ªåœ¨ä»£è¬éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œä¸¦æ¢è¨å…¶åœ¨è½‰æ›è·¯å¾‘ä¸­çš„å…·é«”æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè½‰éŒ„çµ„åˆ†æçµæœé¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢éƒ½æœ‰é¡¯è‘—çš„è®ŠåŒ–ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰å¤šç¨®å¥½è™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¯èƒ½ç„¡æ³•å……åˆ†åˆ©ç”¨å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®è½‰æ›çš„æ©Ÿåˆ¶ä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·è½‰æ›ç‡ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ çš„å¥åº·æ•ˆç›Šå—åˆ°å…¶è½‰æ›æ•ˆç‡çš„å½±éŸ¿ï¼Œå› æ­¤äº†è§£é€™ä¸€éç¨‹å°æ–¼æœªä¾†çš„æ‡‰ç”¨å’Œç ”ç©¶è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æå‡ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æå…¶ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸çš„ä»£è¬è®ŠåŒ–ã€‚é€éè½‰éŒ„çµ„åˆ†æï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£é€™äº›èŒæ ªåœ¨ä»£è¬éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œä¸¦æ¢è¨å…¶åœ¨è½‰æ›è·¯å¾‘ä¸­çš„å…·é«”æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè½‰éŒ„çµ„åˆ†æçµæœé¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢éƒ½æœ‰é¡¯è‘—çš„è®ŠåŒ–ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å°å°çš„åŒ–åˆç‰©ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•è®“ä¹³é…¸èŒï¼ˆå°±æ˜¯é‚£äº›å¹«åŠ©æˆ‘å€‘æ¶ˆåŒ–çš„å¥½èŒï¼‰æ›´æœ‰æ•ˆåœ°å°‡é’èŠ±æ¤°èœè£¡çš„æˆåˆ†è½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…å€‘ç”¨äº†ä¸€äº›æœ‰è¶£çš„å¯¦é©—æŠ€è¡“ï¼Œæƒ³è¦ææ¸…æ¥šé€™å€‹éç¨‹æ˜¯æ€éº¼é‹ä½œçš„ã€‚\n\nå¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘è®“ä¹³é…¸èŒé€²è¡Œäº†é©æ‡‰æ€§é€²åŒ–ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘åœ¨è½‰æ›éç¨‹ä¸­çš„è®ŠåŒ–ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶å¢åŠ äº†æŸç¨®ç³–çš„æ¯”ä¾‹æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒä¸‹é™ï¼Œä½†æ°¨åŸºé…¸ä»£è¬å»æœƒä¸Šå‡ï¼é€™äº›çµæœä¸åƒ…å¹«åŠ©æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªçš„é—œä¿‚ï¼Œé‚„ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ï¼Œå°å¥åº·æœ‰ç›Šï¼\n2. ä¹³é…¸èŒèƒ½å°‡é’èŠ±æ¤°èœä¸­çš„æˆåˆ†è½‰æ›ç‚ºè˜¿è””ç¡«ç´ ï¼Œé€™å€‹éç¨‹å¯ä»¥é€éå¯¦é©—æŠ€è¡“æå‡ã€‚\n3. ç ”ç©¶é¡¯ç¤ºï¼Œç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸çš„ä»£è¬è®ŠåŒ–å°è½‰æ›ç‡æœ‰å½±éŸ¿ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of the study on the conversion of glucosinolates from broccoli into sulforaphane by Lactiplantibacillus plantarum. Include simplified icons of broccoli and sulforaphane, as well as simplified representations of the experimental subjects like humans or cells. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Findings' with simple indicators of the metabolic changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºä¸€äº›å¤©ç„¶ç”¢å“å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„æ²»ç™‚å¯èƒ½ä¸åƒ…é™æ–¼åŒ–ç™‚ï¼Œé‚„å¯ä»¥æ¢ç´¢é€™äº›å¤©ç„¶æˆåˆ†çš„æ‡‰ç”¨ï¼Œç‚ºæ‚£è€…æä¾›æ›´å¤šçš„é¸æ“‡å’Œå¸Œæœ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ¯”ç¾æœ‰æ²»ç™‚æ›´æœ‰æ•ˆçš„é¸æ“‡ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œç„¶å¾Œåœ¨é«”å¤–æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘è©•ä¼°äº†é€™äº›åŒ–åˆç‰©çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦ç‰¹åˆ¥é—œæ³¨äº†å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©17açš„æ•ˆæœã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿ17aå°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºé¡¯è‘—çš„æ•ˆæœï¼Œèˆ‡å…¶ä»–åŒ–åˆç‰©ç›¸æ¯”ï¼Œå…¶IC50å€¼é¡¯ç¤ºå‡ºæ›´é«˜çš„æ•ˆèƒ½ã€‚æ­¤å¤–ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼Œä¸¦èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aä¹ŸæˆåŠŸæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤º17aåœ¨ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ä¸Šå…·æœ‰æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºä¸€äº›å¤©ç„¶ç”¢å“å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„æ²»ç™‚å¯èƒ½ä¸åƒ…é™æ–¼åŒ–ç™‚ï¼Œé‚„å¯ä»¥æ¢ç´¢é€™äº›å¤©ç„¶æˆåˆ†çš„æ‡‰ç”¨ï¼Œç‚ºæ‚£è€…æä¾›æ›´å¤šçš„é¸æ“‡å’Œå¸Œæœ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥è©•ä¼°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœã€‚é€™äº›æ–°åŒ–åˆç‰©çš„ç›®çš„æ˜¯å¸Œæœ›èƒ½æ‰¾åˆ°æ¯”ç¾æœ‰æ²»ç™‚æ›´æœ‰æ•ˆçš„é¸æ“‡ï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°çš„åŒ–åˆç‰©ï¼Œç„¶å¾Œåœ¨é«”å¤–æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘è©•ä¼°äº†é€™äº›åŒ–åˆç‰©çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦ç‰¹åˆ¥é—œæ³¨äº†å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©17açš„æ•ˆæœã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿ17aå°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾å‡ºé¡¯è‘—çš„æ•ˆæœï¼Œèˆ‡å…¶ä»–åŒ–åˆç‰©ç›¸æ¯”ï¼Œå…¶IC50å€¼é¡¯ç¤ºå‡ºæ›´é«˜çš„æ•ˆèƒ½ã€‚æ­¤å¤–ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²ï¼Œä¸¦èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aä¹ŸæˆåŠŸæŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚é€™äº›çµæœé¡¯ç¤º17aåœ¨ä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚ä¸Šå…·æœ‰æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„æ··åˆç‰©åœ¨å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰æ–¹é¢å±•ç¾äº†æ½›åŠ›ï¼Œé€™æ˜¯ä¸€ç¨®ç‰¹åˆ¥ä¾µç•¥æ€§çš„ç™Œç—‡ã€‚ ç ”ç©¶è€…å€‘è¨­è¨ˆäº†15ç¨®æ–°çš„æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—ä¸­æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚\n\nä»–å€‘é¦–å…ˆåˆæˆäº†é€™äº›åŒ–åˆç‰©ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘å¦‚ä½•å½±éŸ¿ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„ç”Ÿé•·ã€‚å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©ï¼Œå«åš17aï¼Œè¡¨ç¾å‡ºç‰¹åˆ¥å¥½çš„æ•ˆæœï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œç”šè‡³èª˜å°ç´°èƒå‡‹äº¡ï¼åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œ17aä¹ŸæˆåŠŸåœ°æŠ‘åˆ¶äº†è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§åæ‡‰ã€‚\n\né€™äº›ç™¼ç¾è®“äººæ„Ÿåˆ°æŒ¯å¥®ï¼Œå› ç‚ºå®ƒå€‘å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¸¶ä¾†æ–°çš„å¸Œæœ›ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„æ··åˆç‰©å¯èƒ½æ˜¯æŠ—ç™Œæ–°é¸æ“‡ã€‚\n2. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ•ˆæœã€‚\n3. é€™äº›çµæœå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that illustrates the experimental process and main results of the study on the potential anti-cancer effects of a compound called 17a. Include simplified icons representing broccoli or daikon (for sulforaphane), experimental subjects like cells or animals, and arrows or flow lines to show the steps of the experiment. Highlight a section labeled 'Main Results' that summarizes the protective effects observed, such as inhibition of cancer cell growth and lack of toxicity.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºèƒ½å¤ æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç‰¹å®šçš„ç’°å¢ƒæˆ–åŠ‘é‡ä¸‹ï¼Œå¯èƒ½æœƒæœ‰æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†å¡«è£œç›®å‰å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­åœ¨è‚ºéƒ¨ç‚ç—‡ä¸­ä½œç”¨çš„çŸ¥è­˜ç©ºç™½ã€‚Nrf2é€šå¸¸è¢«èªç‚ºèƒ½å¤ æŠ‘åˆ¶ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œä½†å…ˆå‰çš„ç ”ç©¶å»é¡¯ç¤ºå®ƒåœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²ç‚ç—‡ï¼Œå› æ­¤æœ¬ç ”ç©¶æ—¨åœ¨æ·±å…¥äº†è§£é€™ç¨®åæ‡‰çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥ä¸€æ¬¡ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©çš„çš®ä¸‹æ³¨å°„ã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æï¼Œä»¥è©•ä¼°è‚ºéƒ¨çš„ç‚ç—‡åæ‡‰ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæš´éœ²æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦æŠ‘åˆ¶äº†IL-6çš„ä¸Šèª¿ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡å…·æœ‰é›™é‡ä½œç”¨ï¼Œå¯èƒ½æ˜¯é€šéNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€çš„ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºèƒ½å¤ æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç‰¹å®šçš„ç’°å¢ƒæˆ–åŠ‘é‡ä¸‹ï¼Œå¯èƒ½æœƒæœ‰æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†å¡«è£œç›®å‰å°æ–¼Nrf2é€™ç¨®è½‰éŒ„å› å­åœ¨è‚ºéƒ¨ç‚ç—‡ä¸­ä½œç”¨çš„çŸ¥è­˜ç©ºç™½ã€‚Nrf2é€šå¸¸è¢«èªç‚ºèƒ½å¤ æŠ‘åˆ¶ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œä½†å…ˆå‰çš„ç ”ç©¶å»é¡¯ç¤ºå®ƒåœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²ç‚ç—‡ï¼Œå› æ­¤æœ¬ç ”ç©¶æ—¨åœ¨æ·±å…¥äº†è§£é€™ç¨®åæ‡‰çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ è¢«éº»é†‰å¾Œé€šéå’½å–‰å¸å…¥ä¸€æ¬¡ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦éš¨å¾Œæ¥å—ç‚ºæœŸ14å¤©çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©çš„çš®ä¸‹æ³¨å°„ã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æï¼Œä»¥è©•ä¼°è‚ºéƒ¨çš„ç‚ç—‡åæ‡‰ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæš´éœ²æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ä»¥åŠè‚ºéƒ¨IL-6è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ å‰‡æ¸›å°‘äº†ç”±å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦æŠ‘åˆ¶äº†IL-6çš„ä¸Šèª¿ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æš´éœ²ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡å…·æœ‰é›™é‡ä½œç”¨ï¼Œå¯èƒ½æ˜¯é€šéNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€çš„ã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± æœ‰æ²’æœ‰æƒ³éï¼Œæ—¥å¸¸åƒçš„è˜¿è””å’Œé’èŠ±æ¤°èœï¼Œç«Ÿç„¶å¯èƒ½å½±éŸ¿æˆ‘å€‘çš„è‚ºéƒ¨å¥åº·å‘¢ï¼Ÿé€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ ï¼ˆå¾é€™äº›è”¬èœä¸­æå–çš„æˆåˆ†ï¼‰å°è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ï¼\n\nç ”ç©¶è€…å€‘ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°æ–¼ç”±å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆé€™æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„ä½œç”¨ã€‚ä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œè®“å°é¼ å¸å…¥ä¸åŒåŠ‘é‡çš„ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘è‚ºéƒ¨çš„ç‚ç—‡å’Œé‡é‡å¢åŠ ï¼Œé‚„æŠ‘åˆ¶äº†æŸäº›ä¿ƒç‚å› å­çš„è¡¨é”ã€‚ä¸éï¼Œä»¤äººé©šè¨çš„æ˜¯ï¼Œåœ¨ä½åŠ‘é‡çš„æƒ…æ³ä¸‹ï¼Œè˜¿è””ç¡«ç´ å»ä¿ƒé€²äº†æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ï¼Œé¡¯ç¤ºå®ƒåœ¨è‚ºéƒ¨ç‚ç—‡ä¸­å¯èƒ½æœ‰é›™é‡ä½œç”¨ï¼\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒæ±¡æŸ“å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ã€‚\n2. åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒå‡ºä¹æ„æ–™ï¼Œç”šè‡³ä¿ƒé€²ç‚ç—‡ã€‚\n3. ç­è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨ï¼Œå°æœªä¾†çš„å¥åº·é é˜²å’Œæ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of a study on the effects of sulforaphane (found in broccoli and radishes) on lung inflammation caused by multi-walled carbon nanotubes. Use a flat design style with a white or light background and soft colors. Include symbols representing sulforaphane, simplified illustrations of experimental subjects (like mice or cells), arrows or flow lines to show the steps of the experiment, and a section highlighting the main results (such as protective effects and changes observed).",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç‚ç—‡ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª˜å°æŸäº›å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°é›£æ²»æ€§ç™Œç—‡çš„æ²»ç™‚ä¸Šã€‚æ­¤å¤–ï¼Œé€™é …ç ”ç©¶é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼äº†è§£ç™Œç—‡æ²»ç™‚è—¥ç‰©çš„å‰¯ä½œç”¨ä¹Ÿéå¸¸é‡è¦ï¼Œå› ç‚ºå¿ƒè‡Ÿå¥åº·å°æ–¼ç™Œç—‡æ‚£è€…çš„æ•´é«”å¥åº·è‡³é—œé‡è¦ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ä»¥åŠå°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆåœ°æ®ºæ­»ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä»¥åŠåœ¨é€™å€‹éç¨‹ä¸­æ˜¯å¦æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆå‚·å®³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä¸¦äº†è§£å…¶å®‰å…¨æ€§ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒç³»ï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒï¼Œä¾†æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ©ç”¨äº†ä¸€ç¨®é è‡¨åºŠçš„é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹çµåˆäº†ä¾†è‡ªäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒï¼Œè®“ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è§€å¯Ÿç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°è©•ä¼°è˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒçš„æ­»äº¡ï¼Œè€Œä¸æœƒå½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŒåŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šæœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡æ²»ç™‚è—¥ç‰©å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ²»ç™‚ä¸­å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª˜å°æŸäº›å‰åˆ—è…ºç™Œç´°èƒçš„æ­»äº¡ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°é›£æ²»æ€§ç™Œç—‡çš„æ²»ç™‚ä¸Šã€‚æ­¤å¤–ï¼Œé€™é …ç ”ç©¶é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼äº†è§£ç™Œç—‡æ²»ç™‚è—¥ç‰©çš„å‰¯ä½œç”¨ä¹Ÿéå¸¸é‡è¦ï¼Œå› ç‚ºå¿ƒè‡Ÿå¥åº·å°æ–¼ç™Œç—‡æ‚£è€…çš„æ•´é«”å¥åº·è‡³é—œé‡è¦ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ä»¥åŠå°å¿ƒè‡Ÿç´°èƒçš„æ½›åœ¨å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆåœ°æ®ºæ­»ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä»¥åŠåœ¨é€™å€‹éç¨‹ä¸­æ˜¯å¦æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆå‚·å®³ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä¸¦äº†è§£å…¶å®‰å…¨æ€§ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒç³»ï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒï¼Œä¾†æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ©ç”¨äº†ä¸€ç¨®é è‡¨åºŠçš„é«”å¤–æ¨¡å‹ï¼Œé€™å€‹æ¨¡å‹çµåˆäº†ä¾†è‡ªäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒçš„å¿ƒè‚Œç´°èƒï¼Œè®“ç ”ç©¶è€…èƒ½å¤ åŒæ™‚è§€å¯Ÿç™Œç´°èƒæ­»äº¡å’Œå¿ƒè‡Ÿçµ„ç¹”çš„æ”¶ç¸®ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°è©•ä¼°è˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒçš„æ­»äº¡ï¼Œè€Œä¸æœƒå½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŒåŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šæœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡æ²»ç™‚è—¥ç‰©å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ²»ç™‚ä¸­å¯èƒ½å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœè£¡é¢è—è‘—æŠ—ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°æŠ—å‰åˆ—è…ºç™Œæœ‰å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç ”ç©¶è€…æƒ³çŸ¥é“å®ƒèƒ½å¦æœ‰æ•ˆæ®ºæ­»ç™Œç´°èƒï¼ŒåŒæ™‚ä¸å‚·å®³å¿ƒè‡Ÿç´°èƒã€‚ä»–å€‘ä½¿ç”¨äº†ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒä¾†é€²è¡Œå¯¦é©—ï¼Œä¸¦è§€å¯Ÿå¿ƒè‡Ÿç´°èƒçš„ç‹€æ³ã€‚\n\nå¯¦é©—çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°æŸäº›ç™Œç´°èƒæ­»äº¡ï¼Œä¸”ä¸æœƒå½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œç•¶ç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒä¸€èµ·åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‡Ÿç´°èƒçš„è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™å¯èƒ½æ„å‘³è‘—è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘ç™Œç—‡æ²»ç™‚çš„å‰¯ä½œç”¨ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—å‰åˆ—è…ºç™Œã€‚\n2. ä¸æœƒæå®³å¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚\n3. æœ‰æ½›åŠ›æ¸›å°‘ç™Œç—‡æ²»ç™‚çš„å‰¯ä½œç”¨ã€‚\n\né›–ç„¶é€™äº›çµæœè®“äººèˆˆå¥®ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of the study on sulforaphane. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like human or cancer cells, and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Findings' highlighting protective effects and changes observed, all in a flat design style with a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éèª¿ç¯€å…ç–«ç³»çµ±ä¾†é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œå¯èƒ½æˆç‚ºæ²»ç™‚æŸäº›ç–¾ç—…çš„æ–°ç­–ç•¥ã€‚ç ”ç©¶ä¸­æåˆ°çš„æ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œé€éæ”¹è®Šé€™äº›ç´°èƒçš„ç‹€æ…‹ï¼Œå¯ä»¥ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œé€²è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚é€™æ¨£çš„ç™¼ç¾å¯èƒ½å°æ–¼é–‹ç™¼é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯ç•¶æˆ‘å€‘è€ƒæ…®åˆ°ç›®å‰æ²»ç™‚é€™äº›ç–¾ç—…çš„æ–¹æ³•ä»ç„¶æœ‰é™æ™‚ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•é€éæ”¹è®Šæ¨¹çªç´°èƒçš„ç‹€æ…‹ä¾†ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œä¸¦ä¸”ç ”ç©¶äº†è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©åœ¨é€™å€‹éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥ä¾¿èƒ½å¤ æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼è‡¨åºŠï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹ï¼Œå¦‚ä½•èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ -å²©è—»ç³–ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­è¡¨ç¾ã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³å°ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè¡ç”Ÿç‰©å°æ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•ä¿ƒé€²å…ç–«è€å—æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œé‚„è§€å¯Ÿåˆ°SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä»¥åŠèª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢å’Œç´°èƒæ¯’æ€§Tç´°èƒå¢æ®–çš„æ¸›å°‘ã€‚åŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±èšç„¦é¡¯å¾®é¡çš„çµæœé¡¯ç¤ºï¼Œåªæœ‰è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1çš„æ´»æ€§å‰‡æ¶ˆé™¤äº†é€™äº›æ•ˆæœï¼Œè­‰å¯¦äº†NFATc1åœ¨è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éèª¿ç¯€å…ç–«ç³»çµ±ä¾†é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œå¯èƒ½æˆç‚ºæ²»ç™‚æŸäº›ç–¾ç—…çš„æ–°ç­–ç•¥ã€‚ç ”ç©¶ä¸­æåˆ°çš„æ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œé€éæ”¹è®Šé€™äº›ç´°èƒçš„ç‹€æ…‹ï¼Œå¯ä»¥ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œé€²è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚é€™æ¨£çš„ç™¼ç¾å¯èƒ½å°æ–¼é–‹ç™¼é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–ç™‚æ³•å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯ç•¶æˆ‘å€‘è€ƒæ…®åˆ°ç›®å‰æ²»ç™‚é€™äº›ç–¾ç—…çš„æ–¹æ³•ä»ç„¶æœ‰é™æ™‚ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•é€éæ”¹è®Šæ¨¹çªç´°èƒçš„ç‹€æ…‹ä¾†ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œä¸¦ä¸”ç ”ç©¶äº†è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©åœ¨é€™å€‹éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥ä¾¿èƒ½å¤ æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼è‡¨åºŠï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡ç‹€æ…‹ä¸‹ï¼Œå¦‚ä½•èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ -å²©è—»ç³–ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­è¡¨ç¾ã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³å°ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè¡ç”Ÿç‰©å°æ¨¹çªç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•ä¿ƒé€²å…ç–«è€å—æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œé‚„è§€å¯Ÿåˆ°SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä»¥åŠèª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢å’Œç´°èƒæ¯’æ€§Tç´°èƒå¢æ®–çš„æ¸›å°‘ã€‚åŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±èšç„¦é¡¯å¾®é¡çš„çµæœé¡¯ç¤ºï¼Œåªæœ‰è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–ä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1çš„æ´»æ€§å‰‡æ¶ˆé™¤äº†é€™äº›æ•ˆæœï¼Œè­‰å¯¦äº†NFATc1åœ¨è˜¿è””ç¡«ç´ -ç”˜éœ²ç³–èª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±å°±åƒä¸€æ”¯ç²¾éŠ³çš„éšŠä¼ï¼Œæ™‚åˆ»æº–å‚™å°æŠ—å¤–ä¾†å…¥ä¾µè€…ï¼Œä½†æœ‰æ™‚å€™å®ƒä¹Ÿæœƒå¤±æ§ï¼Œé€ æˆè‡ªèº«çš„å‚·å®³ã€‚æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œæ¢è¨äº†å¦‚ä½•é€éèª¿æ•´æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®é‡è¦çš„å…ç–«ç´°èƒï¼‰ä¾†å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±æ›´å¥½åœ°é‹ä½œï¼\n\né€™é …ç ”ç©¶çš„ç›®çš„æ˜¯çœ‹çœ‹è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©èƒ½å¦æœ‰æ•ˆæå‡æ¨¹çªç´°èƒçš„ç©©å®šæ€§å’ŒåŠŸèƒ½ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶äººå“¡æŠŠäººé¡çš„å–®æ ¸ç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®ç™½è¡€çƒï¼‰è½‰åŒ–ç‚ºæ¨¹çªç´°èƒï¼Œç„¶å¾Œåœ¨ä¸åŒçš„ç’°å¢ƒä¸­é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿé€™äº›ç´°èƒçš„åæ‡‰ã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ -ç”˜éœ²ç³–é€™ç¨®è¡ç”Ÿç‰©èƒ½å¤ æœ‰æ•ˆèª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿä¸€ç¨®è€å—æ€§è¡¨å‹ï¼Œé€™æ„å‘³è‘—å®ƒå¯ä»¥å¹«åŠ©å…ç–«ç³»çµ±æ¸›å°‘éåº¦åæ‡‰ï¼Œä¿è­·æˆ‘å€‘çš„èº«é«”ä¸å—å‚·å®³ã€‚é€™é …ç™¼ç¾è®“æˆ‘å€‘å°æ–¼æœªä¾†å¯èƒ½é–‹ç™¼å‡ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æ–¹æ³•å……æ»¿æœŸå¾…ï¼\n\nğŸŒŸ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©å¯èƒ½æœ‰åŠ©æ–¼èª¿ç¯€å…ç–«ç³»çµ±ã€‚\n2. æ¨¹çªç´°èƒçš„è€å—æ€§å°æŠ—ç‚ç—‡åæ‡‰è‡³é—œé‡è¦ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç²¾æº–ç™‚æ³•æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on sulforaphane and dendritic cells. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or animal cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸€ç¨®åç‚ºå¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„å¿ƒè‡Ÿç–¾ç—…ã€‚é€™ç¨®ç–¾ç—…æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰èˆ‡TTSçš„ç™¼å±•æœ‰é—œï¼Œå› æ­¤æ‰¾åˆ°é‡å°é€™äº›å•é¡Œçš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ç›¸é—œå¿ƒè‚Œæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ”¹å–„å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿè‚Œè‚‰ç´°èƒï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ä»–å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰ä¾†èª˜å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶åœ˜éšŠè©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç´°èƒå…§çš„éµé›¢å­æ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒä½¿è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„æ²»ç™‚æ•ˆæœæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æ–°çš„è¦‹è§£ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸€ç¨®åç‚ºå¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰çš„å¿ƒè‡Ÿç–¾ç—…ã€‚é€™ç¨®ç–¾ç—…æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰èˆ‡TTSçš„ç™¼å±•æœ‰é—œï¼Œå› æ­¤æ‰¾åˆ°é‡å°é€™äº›å•é¡Œçš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ç›¸é—œå¿ƒè‚Œæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ”¹å–„å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿè‚Œè‚‰ç´°èƒï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚ä»–å€‘ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ï¼ˆisoproterenolï¼‰ä¾†èª˜å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶åœ˜éšŠè©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç´°èƒå…§çš„éµé›¢å­æ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒä½¿è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„æ²»ç™‚æ•ˆæœæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å¿ƒè‡Ÿç–¾ç—…å«å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ï¼ˆTTSï¼‰ï¼Œå®ƒå¯èƒ½æ¯”æˆ‘å€‘æƒ³åƒçš„é‚„è¦åš´é‡ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®ç–¾ç—…é›–ç„¶æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°å¿ƒè‡Ÿé€ æˆå±éšªçš„æå‚·ã€‚ç ”ç©¶äººå“¡åœ¨æ¢ç´¢ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œçœ‹çœ‹å®ƒèƒ½å¦å¹«åŠ©æ¸›è¼•TTSé€ æˆçš„å‚·å®³ã€‚\n\né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒï¼Œæ¨¡æ“¬TTSçš„æƒ…æ³ï¼Œä¸¦ç”¨ç•°ä¸™è…ä¸Šè…ºç´ é€™ç¨®è—¥ç‰©ä¾†èª˜å°å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ã€‚æ¥è‘—ï¼Œä»–å€‘è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè©•ä¼°å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„å¢å¼·äº†æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘äº†ç´°èƒæå‚·ï¼Œä¸¦æŠ‘åˆ¶äº†éµæ­»äº¡çš„ç›¸é—œæŒ‡æ¨™ã€‚é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„é›™é‡ç™‚æ³•ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°æ€è·¯ã€‚\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„å½±éŸ¿ã€‚\n3. ç ”ç©¶çµæœç‚ºTTSçš„æ²»ç™‚é–‹å•Ÿäº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on sulforaphane's effects on Takotsubo syndrome (TTS). Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects (like animals or cells), and arrows or flow lines to indicate the experimental steps. Include a section that clearly lists the main results, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¡”ç§‘èŒ²åšç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ç­‰å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨ç´°èƒï¼Œæ¸›å°‘å¸ç…™é€ æˆçš„æå®³ï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥åº·è­°é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©å¼•èµ·çš„äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿SIRT1é€™å€‹åŸºå› çš„è¡¨é”ï¼Œå› ç‚ºé€™å€‹åŸºå› èˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œå­˜æ´»èƒ½åŠ›æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨å°æŠ—å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·ä¸­çš„æ½›åœ¨è§’è‰²ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†BEAS-2Bé€™ç¨®äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ä¸­ï¼Œä»¥è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚ä»–å€‘ä½¿ç”¨MTTæ¸¬è©¦ä¾†æ¸¬é‡ç´°èƒçš„æ´»æ€§ï¼Œä¸¦é€éSA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ†æäº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¸¦æ¸¬é‡äº†æ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œå‰‡ä½¿ç”¨äº†èª˜å°è‚ºæ°£è…«çš„æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿ä»¥åŠNF-ÎºBçš„ä¸Šèª¿ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¹ŸæŠ‘åˆ¶äº†å¸ç…™æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ç­‰å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨ç´°èƒï¼Œæ¸›å°‘å¸ç…™é€ æˆçš„æå®³ï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥åº·è­°é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©å¼•èµ·çš„äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿SIRT1é€™å€‹åŸºå› çš„è¡¨é”ï¼Œå› ç‚ºé€™å€‹åŸºå› èˆ‡ç´°èƒçš„å£“åŠ›æŠµæŠ—å’Œå­˜æ´»èƒ½åŠ›æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨å°æŠ—å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·ä¸­çš„æ½›åœ¨è§’è‰²ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†BEAS-2Bé€™ç¨®äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ä¸­ï¼Œä»¥è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚ä»–å€‘ä½¿ç”¨MTTæ¸¬è©¦ä¾†æ¸¬é‡ç´°èƒçš„æ´»æ€§ï¼Œä¸¦é€éSA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ†æäº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œä¸¦æ¸¬é‡äº†æ°§åŒ–å£“åŠ›æŒ‡æ¨™å’Œç´°èƒå…§çš„éµå«é‡ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œå‰‡ä½¿ç”¨äº†èª˜å°è‚ºæ°£è…«çš„æ¨¡å‹ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿ä»¥åŠNF-ÎºBçš„ä¸Šèª¿ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¹ŸæŠ‘åˆ¶äº†å¸ç…™æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ï¼ŒçœŸçš„æ˜¯ä¸€å€‹ä¸å®¹å¿½è¦–çš„å¥åº·è­°é¡Œï¼é€™æ¬¡çš„ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†ä¸€å€‹æœ‰è¶£çš„å¸Œæœ›â€”â€”è˜¿è””ç¡«ç´ ï¼\n\nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™é€ æˆçš„ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ä»–å€‘ç”¨äººé¡æ°£é“çš„ç´°èƒå’Œå°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œçµæœé¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒçš„æ¯’æ€§å’Œè€åŒ–ç¾è±¡ã€‚\n\nå…·é«”ä¾†èªªï¼Œè˜¿è””ç¡«ç´ å¯ä»¥æ”¹å–„å°é¼ çš„è‚ºéƒ¨ç—…ç†è®ŠåŒ–ï¼Œä¸¦å¹«åŠ©é€†è½‰ä¸€äº›èˆ‡å¸ç…™ç›¸é—œçš„åŸºå› è¡¨é”è®ŠåŒ–ã€‚é€™æ„å‘³è‘—ï¼Œå®ƒå¯èƒ½åœ¨å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–ä¸Šï¼Œæä¾›äº†ä¸€äº›ä¿è­·ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨ç´°èƒï¼Œæ¸›å°‘å¸ç…™é€ æˆçš„æå®³ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ”¹å–„ç´°èƒçš„å­˜æ´»ç‡å’Œæ¸›å°‘è€åŒ–ã€‚\n3. è˜¿è””ç¡«ç´ å¯èƒ½é€†è½‰å¸ç…™å°æŸäº›åŸºå› çš„å½±éŸ¿ï¼Œæä¾›é¡å¤–çš„ä¿è­·ä½œç”¨ã€‚\n\né›–ç„¶é€™äº›çµæœå¾ˆé¼“èˆï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†æ·±å…¥äº†è§£å®ƒçš„æ½›åŠ›ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. Use a simple and clear design style with flat illustrations on a white or light background. Include symbols representing broccoli or sulforaphane, simplified illustrations of human cells and mice, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œæ˜¯å¦èƒ½åœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚äº†è§£é€™ç¨®ç‰©è³ªçš„æ½›åœ¨æ•ˆæœï¼Œå°æ–¼æ”¹å–„çš®è†šå¥åº·å’Œé é˜²èˆ‡å¹´é½¡ç›¸é—œçš„å•é¡Œå…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨ç•¶ä»Šç¤¾æœƒä¸­ï¼Œè¶Šä¾†è¶Šå¤šäººé—œæ³¨æŠ—è€åŒ–çš„ç”¢å“å’Œæ–¹æ³•ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒåœ¨æŠ—è€åŒ–éç¨‹ä¸­å¯èƒ½çš„æ©Ÿåˆ¶ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è©¦åœ–æ‰¾å‡ºè˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ï¼Œä¸¦è­˜åˆ¥å‡ºèˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼ŒæŒçºŒå…©å€‹æœˆï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–éç¨‹ä¸­è›‹ç™½è³ªè¡¨é”çš„å½±éŸ¿ï¼Œå¾è€Œæ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”åœ¨è£œå……å¾Œçš„å…©å€‹æœˆå…§ï¼Œçš®è†šçµæ§‹å’Œå…ç–«ç´°èƒçš„çµ„æˆéƒ½æœ‰æ‰€æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨é”æ¨¡å¼ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ ä¿ƒé€²çš„ä¿¡è™Ÿé€šè·¯ä¸­ï¼Œç™¼ç¾äº†233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œç‚ºæœªä¾†çš„æŠ—è€åŒ–ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œæ˜¯å¦èƒ½åœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚äº†è§£é€™ç¨®ç‰©è³ªçš„æ½›åœ¨æ•ˆæœï¼Œå°æ–¼æ”¹å–„çš®è†šå¥åº·å’Œé é˜²èˆ‡å¹´é½¡ç›¸é—œçš„å•é¡Œå…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨ç•¶ä»Šç¤¾æœƒä¸­ï¼Œè¶Šä¾†è¶Šå¤šäººé—œæ³¨æŠ—è€åŒ–çš„ç”¢å“å’Œæ–¹æ³•ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒåœ¨æŠ—è€åŒ–éç¨‹ä¸­å¯èƒ½çš„æ©Ÿåˆ¶ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è©¦åœ–æ‰¾å‡ºè˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ï¼Œä¸¦è­˜åˆ¥å‡ºèˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼ŒæŒçºŒå…©å€‹æœˆï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–éç¨‹ä¸­è›‹ç™½è³ªè¡¨é”çš„å½±éŸ¿ï¼Œå¾è€Œæ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”åœ¨è£œå……å¾Œçš„å…©å€‹æœˆå…§ï¼Œçš®è†šçµæ§‹å’Œå…ç–«ç´°èƒçš„çµ„æˆéƒ½æœ‰æ‰€æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªè¡¨é”æ¨¡å¼ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ ä¿ƒé€²çš„ä¿¡è™Ÿé€šè·¯ä¸­ï¼Œç™¼ç¾äº†233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œç‚ºæœªä¾†çš„æŠ—è€åŒ–ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒæ…¢æ…¢è®Šå¾—ä¸é‚£éº¼ç·Šç·»ï¼Œç”šè‡³å‡ºç¾è€åŒ–çš„ç¾è±¡ã€‚é€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½è®“æˆ‘å€‘çš„èº«é«”è®Šå¾—è„†å¼±ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„å¤©ç„¶ç‰©è³ªï¼Œçœ‹çœ‹å®ƒæ˜¯å¦èƒ½å¹«åŠ©æˆ‘å€‘æ¸›ç·©çš®è†šè€åŒ–çš„éç¨‹ã€‚ ç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ å°±åƒæˆ‘å€‘çš„çš®è†šä¸€æ¨£ï¼Œéš¨è‘—æ™‚é–“è®Šè€ã€‚ä»–å€‘å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼ŒæŒçºŒäº†å…©å€‹æœˆï¼Œç„¶å¾Œè§€å¯Ÿçš®è†šçš„è®ŠåŒ–ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„å°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½ï¼è€Œä¸”åœ¨é€™æ®µæ™‚é–“å…§ï¼Œçš®è†šçš„å¥åº·ç‹€æ³æœ‰äº†æ˜é¡¯çš„æå‡ã€‚é€™é …ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å½±éŸ¿çš®è†šä¸­ä¸€äº›é‡è¦è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™ç‚ºæœªä¾†æŠ—è€åŒ–çš„ç ”ç©¶æä¾›äº†æ–°çš„æ€è·¯ã€‚âœ¨ ä¸»è¦é‡é»ï¼š 1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„çš®è†šè€åŒ–ã€‚ 2. ç ”ç©¶ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ 3. è˜¿è””ç¡«ç´ èƒ½å½±éŸ¿çš®è†šä¸­çš„è›‹ç™½è³ªè¡¨é”ï¼Œç‚ºæŠ—è€åŒ–ç ”ç©¶é–‹å•Ÿæ–°æ–¹å‘ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of the study on sulforaphane. The background should be white or light-colored with soft color tones. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, and arrows or flow lines to indicate the steps of the experiment. Add a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼å°‹æ±‚æ”¹å–„è‚è‡Ÿå¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„ç™¼ç¾ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©æ¸›å°‘æŸäº›ç’°å¢ƒæ¯’ç´ å°èº«é«”çš„å‚·å®³ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ¯’ç´ å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£ç’°å¢ƒæ¯’ç´ çš„å±å®³ï¼Œä¹Ÿå¯èƒ½ç‚ºæ”¹å–„å¥åº·æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•ä¸‰è‹¯éŒ«çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦ä¸”å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œç•¶æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¾—åˆ°äº†ç·©è§£ï¼Œè‚è‡Ÿçš„ä»£è¬ç‹€æ…‹å¾—ä»¥æ¢å¾©ï¼Œä¸¦ä¸”è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œå¢åŠ äº†æœ‰ç›ŠèŒç¾¤ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·å½±éŸ¿æ–¹é¢æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œæä¾›äº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼å°‹æ±‚æ”¹å–„è‚è‡Ÿå¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„ç™¼ç¾ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©æ¸›å°‘æŸäº›ç’°å¢ƒæ¯’ç´ å°èº«é«”çš„å‚·å®³ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ¯’ç´ å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£ç’°å¢ƒæ¯’ç´ çš„å±å®³ï¼Œä¹Ÿå¯èƒ½ç‚ºæ”¹å–„å¥åº·æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•ä¸‰è‹¯éŒ«çš„æ¯’æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦ä¸”å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œç•¶æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¾—åˆ°äº†ç·©è§£ï¼Œè‚è‡Ÿçš„ä»£è¬ç‹€æ…‹å¾—ä»¥æ¢å¾©ï¼Œä¸¦ä¸”è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œå¢åŠ äº†æœ‰ç›ŠèŒç¾¤ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·å½±éŸ¿æ–¹é¢æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œæä¾›äº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿåƒè˜¿è””ç«Ÿç„¶å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±ï¼é€™æ˜¯ä¸€é …æ–°ç ”ç©¶çš„ç™¼ç¾ï¼Œè®“æˆ‘å€‘ä¾†çœ‹çœ‹è£¡é¢æœ‰ä»€éº¼æœ‰è¶£çš„å…§å®¹ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„ç‰©è³ªï¼Œç ”ç©¶è€…æƒ³çŸ¥é“å®ƒèƒ½å¦å¹«åŠ©å°æŠ—ä¸€ç¨®ç’°å¢ƒæ¯’ç´ â€”â€”ä¸‰è‹¯éŒ«ï¼Œé€™ç¨®æ¯’ç´ å°é­šé¡çš„å¥åº·æœ‰ä¸è‰¯å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„è§€å¯Ÿã€‚ä¸€çµ„æ²’æœ‰ä»»ä½•è™•ç†ï¼Œå¦ä¸€çµ„å‰‡æ¥å—äº†ä¸‰è‹¯éŒ«ï¼Œæœ€å¾Œä¸€çµ„å‰‡åŒæ™‚æ¥å—äº†ä¸‰è‹¯éŒ«å’Œè˜¿è””ç¡«ç´ ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†ä¸‹é­šé¡çš„å¥åº·ç‹€æ³ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦æœƒé€ æˆè‚è‡Ÿçš„å‚·å®³ï¼Œä½†ç•¶åŠ å…¥è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¾—åˆ°äº†ç·©è§£ï¼Œè‚è‡Ÿçš„å¥åº·ç‹€æ…‹ä¹Ÿæœ‰æ‰€æ”¹å–„ï¼Œç”šè‡³è…¸é“ä¸­çš„æœ‰ç›ŠèŒç¾¤ä¹Ÿå¢åŠ äº†ï¼\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç’°å¢ƒæ¯’ç´ çš„å½±éŸ¿ã€‚\n2. å®ƒæœ‰åŠ©æ–¼æ”¹å–„è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±ã€‚\n3. å¢åŠ æœ‰ç›ŠèŒç¾¤ï¼Œä¿ƒé€²è…¸é“å¥åº·ã€‚\n\næ‰€ä»¥ï¼Œä¸‹æ¬¡åƒè˜¿è””æ™‚ï¼Œåˆ¥å¿˜äº†å®ƒçš„å¥åº·å¥½è™•å“¦ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main findings of a study on the protective effects of daikon sulforaphane against environmental toxins. The image should have a flat design style with a white or light-colored background and soft color palette. Include symbols representing daikon or sulforaphane, simplified illustrations of experimental subjects like fish, and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' showing protective effects and changes in health indicators.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„éšœç¤™èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œæ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼é é˜²å’Œç®¡ç†ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿å¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„é—œéµå› ç´ ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°çš„ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–åŠå…¶ä»£è¬ç‰©çš„è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬ç‰©åˆ†æä¸­ç™¼ç¾ï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–å¾—åˆ°äº†é¡¯è‘—æ”¹å–„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ¸›è¼•çµè…¸ç‚çš„ç—‡ç‹€ï¼Œä¸¦æ”¹å–„è…¸é“åŠŸèƒ½ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„éšœç¤™èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œæ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼é é˜²å’Œç®¡ç†ç›¸é—œç–¾ç—…æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿å¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„é—œéµå› ç´ ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°çš„ã€‚ç ”ç©¶è€…çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆè®ŠåŒ–åŠå…¶ä»£è¬ç‰©çš„è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬ç‰©åˆ†æä¸­ç™¼ç¾ï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–å¾—åˆ°äº†é¡¯è‘—æ”¹å–„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ¸›è¼•çµè…¸ç‚çš„ç—‡ç‹€ï¼Œä¸¦æ”¹å–„è…¸é“åŠŸèƒ½ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“å¥åº·å…¶å¯¦è·Ÿæˆ‘å€‘åƒçš„é£Ÿç‰©æ¯æ¯ç›¸é—œï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„è…¸é“æœ‰å¾ˆå¤§çš„å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚çš„å½±éŸ¿ï¼Œé€™æ˜¯ä¸€ç¨®æœƒé€ æˆè…¸é“ç™¼ç‚çš„ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†é€²è¡Œå¯¦é©—ï¼Œçµ¦å°é¼ æ³¨å…¥è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„è…¸é“å¥åº·ç‹€æ³ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å°é¼ çš„è…¸é“å±éšœï¼Œé‚„èƒ½æ¸›å°‘è…¸é“çš„ç‚ç—‡ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„ç®¡ç†éå¸¸é‡è¦ï¼æ­¤å¤–ï¼Œè…¸é“å…§çš„å¾®ç”Ÿç‰©ç¾¤ä¹Ÿå› ç‚ºè˜¿è””ç¡«ç´ çš„å½±éŸ¿è€Œå¾—åˆ°äº†é‡æ–°å¹³è¡¡ï¼Œé€™æ„å‘³è‘—è…¸é“çš„å¥åº·ç‹€æ…‹æœ‰äº†æ”¹å–„ã€‚\n\nâœ¨ é€™è£¡æœ‰å¹¾å€‹å°é‡é»è¦å’Œå¤§å®¶åˆ†äº«ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ã€‚\n2. æ¸›å°‘è…¸é“ç‚ç—‡å°æ–¼é é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚\n3. è˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆï¼Œä¿ƒé€²è…¸é“å¥åº·ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨è…¸é“å¥åº·ï¼Œä¿æŒè‰¯å¥½çš„é£²é£Ÿç¿’æ…£å§ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include simplified illustrations of broccoli or a symbol representing sulforaphane. Depict a small mouse as the experimental subject. Use arrows or flow lines to show the experimental steps, such as 'Administer sulforaphane' and 'Observe intestinal health'. Add a section labeled 'Main Results' highlighting protective effects and changes in gut health, such as 'Improved gut barrier' and 'Reduced inflammation'. Use soft colors to make it visually appealing.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹è‰¯çš„ç´ç±³æŠ€è¡“ä¾†å‚³éè˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœƒå¢å¼·å…¶æŠ—è…«ç˜¤æ•ˆæœï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•æ›´æœ‰æ•ˆåœ°ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡ï¼Œé‚„å¯èƒ½ç‚ºå…¶ä»–ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†æé«˜å…¶ç™‚æ•ˆã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†ç‚ºå…­çµ„ï¼Œé€²è¡Œä¸åŒçš„è™•ç†ã€‚å¯¦é©—çµ„åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ï¼Œå¾Œè€…å‰‡åˆ†åˆ¥æ¥å—è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„æ²»ç™‚ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ï¼Œä»¥è©•ä¼°æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAç¢ç‰‡å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡åŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰æŠ—ç™Œç‰¹æ€§ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ”¹è‰¯çš„ç´ç±³æŠ€è¡“ä¾†å‚³éè˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœƒå¢å¼·å…¶æŠ—è…«ç˜¤æ•ˆæœï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•æ›´æœ‰æ•ˆåœ°ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡ï¼Œé‚„å¯èƒ½ç‚ºå…¶ä»–ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯ä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†æé«˜å…¶ç™‚æ•ˆã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†ç‚ºå…­çµ„ï¼Œé€²è¡Œä¸åŒçš„è™•ç†ã€‚å¯¦é©—çµ„åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ï¼Œå¾Œè€…å‰‡åˆ†åˆ¥æ¥å—è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„æ²»ç™‚ã€‚æ²»ç™‚æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ï¼Œä»¥è©•ä¼°æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAç¢ç‰‡å’Œæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡åŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ç¨®å¾ˆå²å®³çš„æˆåˆ†å«åšè˜¿è””ç¡«ç´ å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™å€‹æˆåˆ†åœ¨æŠ—ç™Œæ–¹é¢å¯èƒ½æœ‰æ›´å¤§çš„æ½›åŠ›ï¼ç ”ç©¶è€…å€‘å°è˜¿è””ç¡«ç´ é€²è¡Œäº†æ·±å…¥æ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°é¼ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚\n\nä»–å€‘ä½¿ç”¨äº†90éš»å°é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå¹¾çµ„ï¼Œçµ¦äºˆä¸åŒçš„è™•ç†æ–¹å¼ï¼ŒåŒ…æ‹¬å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ å’Œç”¨ç´ç±³æŠ€è¡“æ”¹è‰¯çš„è˜¿è””ç¡«ç´ ã€‚é€™æ¨£çš„è¨­è¨ˆè®“ä»–å€‘å¯ä»¥è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœå’Œä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç¶“é20å¤©çš„å¯¦é©—ï¼Œç ”ç©¶ç™¼ç¾ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æœ‰æ•ˆæ¸›å°‘è…«ç˜¤é«”ç©ï¼Œé‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨æŠ—è…«ç˜¤å’ŒæŠ—ç‚æ–¹é¢çš„æ½›åŠ›ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’ŒåŸºå› è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚  \n2. ç´ç±³è„‚è³ªé«”å½¢å¼çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´ä½³ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create an informative flat design illustration that explains the experimental process and main findings of a study on sulforaphane. Include symbols representing broccoli and sulforaphane, simplified icons of experimental subjects like mice or cells, and arrows or flow lines to indicate the experimental steps. Add a section highlighting the main results, such as protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Ehrlichè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºç›®å‰å°èƒƒç™Œçš„æ²»ç™‚é¸æ“‡ç›¸å°æœ‰é™ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²ä¸€æ­¥é©—è­‰äº†èˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œä»¥æ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ï¼Œå› ç‚ºç›®å‰å°èƒƒç™Œçš„æ²»ç™‚é¸æ“‡ç›¸å°æœ‰é™ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ï¼ŒåŒ…æ‹¬é«”å¤–å’Œé«”å…§çš„æ¸¬è©¦ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é‚„é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²ä¸€æ­¥é©—è­‰äº†èˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œä»¥æ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤æ¡Œä¸Šå¯èƒ½éš±è—è‘—å°æŠ—èƒƒç™Œçš„è¶…ç´šé£Ÿæï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ–°å¸Œæœ›ã€‚é€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦å°‹æ‰¾å…¶èƒŒå¾Œçš„é‹ä½œæ©Ÿåˆ¶ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†å¤šç¨®å¯¦é©—ï¼ŒåŒ…æ‹¬åœ¨è©¦ç®¡å’Œå‹•ç‰©é«”å…§æ¸¬è©¦è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œé‚„åˆ†æäº†ç›¸é—œçš„åŸºå› ï¼Œæƒ³è¦æ›´æ·±å…¥äº†è§£å®ƒçš„ä½œç”¨ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé‚„èƒ½é™ä½ä¸€ç¨®å«CKMT2-AS1çš„ç‰©è³ªçš„è¡¨é”ï¼Œé€™ç¨®ç‰©è³ªçš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ã€‚\n2. CKMT2-AS1çš„é«˜è¡¨é”èˆ‡ç”Ÿå­˜ç‡ä½æœ‰é—œã€‚\n3. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚èƒƒç™Œçš„æ–°é¶é»ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the effects of sulforaphane on stomach cancer. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½ç‚ºè‡ªé–‰ç—‡çš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ›´å¤šå®¶åº­é¢å°é€™å€‹æŒ‘æˆ°ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€éç³»çµ±æ€§å›é¡§å’Œåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼è©•ä¼°è˜¿è””ç¡«ç´ çš„å¯¦éš›æ•ˆæœï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œéƒ½é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­æœ‰åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šå€‹ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½èˆ‡å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨æœ‰é—œã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†åˆæ­¥çš„æ”¯æŒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°æ–¼å®ƒçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½ç‚ºè‡ªé–‰ç—‡çš„é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ›´å¤šå®¶åº­é¢å°é€™å€‹æŒ‘æˆ°ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆåŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›é€éç³»çµ±æ€§å›é¡§å’Œåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼è©•ä¼°è˜¿è””ç¡«ç´ çš„å¯¦éš›æ•ˆæœï¼Œä¹Ÿèƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿ç ”ç©¶è€…èƒ½å¤ æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œéƒ½é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­æœ‰åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šå€‹ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½èˆ‡å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨æœ‰é—œã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†åˆæ­¥çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœä¸åªæ˜¯è®“ä½ æ›´å¥åº·ï¼Œé‚„å¯èƒ½å°è‡ªé–‰ç—‡å­©å­æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œå®ƒä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘çš„è”¬èœä¸­ï¼Œåƒæ˜¯é’èŠ±æ¤°èœã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦æ­ç¤ºå®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä»–å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æ¶‰åŠäº†333ååƒèˆ‡è€…ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†è¨±å¤šæ–¹æ³•ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œä¸è«–æ˜¯è£œå……4-5é€±é‚„æ˜¯8-10é€±ï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰éƒ½æ˜é¡¯æ”¹å–„ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰é¡¯è‘—é€²æ­¥ï¼Œä¸”æ²’æœ‰ç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•ä¸­çš„æ½›åŠ›æœ‰äº†åˆæ­¥çš„èªè­˜ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰ã€‚\n2. ç ”ç©¶é¡¯ç¤ºè£œå……è˜¿è””ç¡«ç´ å¾Œï¼Œåƒèˆ‡è€…çš„è¡¨ç¾æœ‰é¡¯è‘—æå‡ã€‚\n3. ç›®å‰æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„å‰¯ä½œç”¨ï¼Œé€™æ˜¯å€‹å¥½æ¶ˆæ¯ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental methods and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified figures of human or animal subjects, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting the protective effects observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªå­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œä¸¦ä¸”å·²çŸ¥å…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤æ‚£è€…çš„å¥åº·ç‹€æ³æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªæ–¹é¢ã€‚é€™å°æ–¼æœªä¾†çš„ç§»æ¤æ²»ç™‚å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå¯èƒ½æœƒä¿ƒé€²æ›´æœ‰æ•ˆçš„å…ç–«æŠ‘åˆ¶ç­–ç•¥çš„ç™¼å±•ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œä¸¦ä¸”æ¢ç´¢å…¶åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ä»¥åŠç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶ä¸»é¡Œï¼Œå› ç‚ºæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ç§»æ¤æ‰‹è¡“å¾Œçš„ä¸€å€‹ä¸»è¦æŒ‘æˆ°ï¼Œäº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„ä½œç”¨å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤çµæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡ä¾†è‡ªBalb/cå°é¼ çš„çš®è†šç§»æ¤åˆ°C57BL/6å°é¼ èº«ä¸Šã€‚ç‚ºäº†æé«˜è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç ”ç©¶åœ˜éšŠå°‡å…¶èˆ‡é€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆäº†ä¸€ç¨®ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç‰¹æ€§åˆ†æã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚é€™äº›æ–¹æ³•çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ä¸­çš„æ½›åŠ›ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ï¼Œèˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œç¶“éæ²»ç™‚çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤æˆåŠŸç‡ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ç ”ç©¶ä¸­çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠè©¦é©—æä¾›äº†åŸºç¤ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªå­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œä¸¦ä¸”å·²çŸ¥å…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤æ‚£è€…çš„å¥åº·ç‹€æ³æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªæ–¹é¢ã€‚é€™å°æ–¼æœªä¾†çš„ç§»æ¤æ²»ç™‚å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå¯èƒ½æœƒä¿ƒé€²æ›´æœ‰æ•ˆçš„å…ç–«æŠ‘åˆ¶ç­–ç•¥çš„ç™¼å±•ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œä¸¦ä¸”æ¢ç´¢å…¶åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ä»¥åŠç§»æ¤å™¨å®˜çš„å­˜æ´»æƒ…æ³ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶ä¸»é¡Œï¼Œå› ç‚ºæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ç§»æ¤æ‰‹è¡“å¾Œçš„ä¸€å€‹ä¸»è¦æŒ‘æˆ°ï¼Œäº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„ä½œç”¨å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤çµæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡ä¾†è‡ªBalb/cå°é¼ çš„çš®è†šç§»æ¤åˆ°C57BL/6å°é¼ èº«ä¸Šã€‚ç‚ºäº†æé«˜è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç ”ç©¶åœ˜éšŠå°‡å…¶èˆ‡é€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆäº†ä¸€ç¨®ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†ç‰¹æ€§åˆ†æã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚é€™äº›æ–¹æ³•çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ä¸­çš„æ½›åŠ›ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½é¡¯è‘—æé«˜ç§»æ¤çš®è†šçš„å­˜æ´»ç‡ï¼Œèˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œç¶“éæ²»ç™‚çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤æˆåŠŸç‡ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ç ”ç©¶ä¸­çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠè©¦é©—æä¾›äº†åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„æˆåˆ†ï¼Œå°æ–¼å™¨å®˜ç§»æ¤å¾Œçš„æ’æ–¥åæ‡‰æœ‰è‘—æ½›åœ¨çš„æ­£é¢å½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©é™ä½æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œç ”ç©¶åœ˜éšŠä½¿ç”¨å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡çš®è†šç§»æ¤åˆ°ä¸åŒçš„å°é¼ èº«ä¸Šï¼Œä¸¦å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆä¸€ç¨®ç‰¹æ®Šçš„æ°´å‡è† ä¾†é€²è¡Œæ¸¬è©¦ã€‚çµæœé¡¯ç¤ºï¼Œä½¿ç”¨é€™ç¨®æ°´å‡è† çš„å°é¼ åœ¨14å¤©å…§æœ‰é«˜é”80%çš„ç§»æ¤æˆåŠŸç‡ï¼Œé€™æ˜¯ç›¸ç•¶é©šäººçš„æ•¸å­—ï¼è€Œä¸”ï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡ä¹Ÿè¼ƒå°‘ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚\n\né€™é …ç ”ç©¶ä¸åƒ…è®“æˆ‘å€‘å°å™¨å®˜ç§»æ¤çš„æœªä¾†å……æ»¿å¸Œæœ›ï¼Œä¹Ÿç‚ºæ”¹å–„ç§»æ¤æ‚£è€…çš„å¥åº·ç‹€æ³æä¾›äº†æ–°çš„æ€è·¯ã€‚ä»¥ä¸‹æ˜¯å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ã€‚\n2. ä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† å¯é¡¯è‘—æé«˜çš®è†šç§»æ¤çš„æˆåŠŸç‡ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡¨åºŠè©¦é©—å¥ å®šäº†åŸºç¤ã€‚",
    "image_prompt": "Create an informative flat design illustration on a light background that explains the experiment and main results of a study on sulforaphane. Include simplified graphics of broccoli or sulforaphane, mice as experimental subjects, and arrows or flow lines to indicate the experimental steps. Add a section that highlights the main results, such as the protective effects observed and the success rate of skin transplants.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°å°æŠ—ç™Œç—‡åŠå…¶ç›¸é—œçš„ç‚ç—‡åæ‡‰ã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®åŒ–åˆç‰©å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»åŠç‚ç—‡ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿèƒ½ç‚ºå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æä¾›ç†è«–åŸºç¤ã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å„ç¨®ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™æ¨£çš„ç ”ç©¶æ–¹æ³•èƒ½å¤ å…¨é¢åœ°è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åƒè€ƒã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰å¤šæ–¹é¢çš„æ½›åŠ›ï¼Œèƒ½å¤ å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©å­¸é€”å¾‘ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜å®ƒåœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½å…·æœ‰ä¸€å®šçš„æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚å› æ­¤ï¼Œè˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ä»ç„¶æ˜¯ä¸€å€‹å€¼å¾—æ·±å…¥æ¢ç´¢çš„é ˜åŸŸã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°å°æŠ—ç™Œç—‡åŠå…¶ç›¸é—œçš„ç‚ç—‡åæ‡‰ã€‚\n\né€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®åŒ–åˆç‰©å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿å¤šç¨®ç”Ÿç‰©å­¸é€”å¾‘ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»åŠç‚ç—‡ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿèƒ½ç‚ºå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æä¾›ç†è«–åŸºç¤ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°æ–¼å„ç¨®ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™æ¨£çš„ç ”ç©¶æ–¹æ³•èƒ½å¤ å…¨é¢åœ°è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœï¼Œä¸¦ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›åƒè€ƒã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰å¤šæ–¹é¢çš„æ½›åŠ›ï¼Œèƒ½å¤ å½±éŸ¿å¤šç¨®èˆ‡ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©å­¸é€”å¾‘ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜å®ƒåœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½å…·æœ‰ä¸€å®šçš„æ•ˆæœï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚å› æ­¤ï¼Œè˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ä»ç„¶æ˜¯ä¸€å€‹å€¼å¾—æ·±å…¥æ¢ç´¢çš„é ˜åŸŸã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ç¨®ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒå¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©å“¦ï¼é€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºï¼Œæ¯”å¦‚ä¿ƒé€²æˆ–æŠ‘åˆ¶ç´°èƒç”Ÿé•·ã€å½±éŸ¿è¡€ç®¡ç”Ÿæˆï¼ˆè¡€ç®¡çš„å½¢æˆï¼‰ä»¥åŠå¼•ç™¼ç´°èƒæ­»äº¡ç­‰ã€‚\n\nä»–å€‘é€éæ–‡ç»å›é¡§ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©åˆ†å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸€äº›è·Ÿç‚ç—‡å’Œç´°èƒæ­»äº¡æœ‰é—œçš„è›‹ç™½è³ªã€‚é‚„æœ‰ï¼Œç ”ç©¶è€…å€‘ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“åœ¨é€™è£¡çš„æ‡‰ç”¨ï¼Œé€™æ¨£çš„æ–¹å¼è®“æˆ‘å€‘èƒ½æ›´å…¨é¢åœ°äº†è§£è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æœ‰å¤šæ–¹é¢çš„æ½›åŠ›ï¼Œé›–ç„¶ç›®å‰çš„ç ”ç©¶çµæœçœ‹èµ·ä¾†ä¸éŒ¯ï¼Œä½†ä»éœ€è¦æ›´å¤šçš„å¯¦é©—ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚ç¸½ä¹‹ï¼Œè˜¿è””ç¡«ç´ çš„ç ”ç©¶å€¼å¾—æˆ‘å€‘ç¹¼çºŒé—œæ³¨ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚\n2. ç ”ç©¶æ¢è¨å…¶å°ç™Œç´°èƒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å°ç´°èƒç”Ÿé•·å’Œæ­»äº¡çš„èª¿æ§ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªå…¶æ•ˆæœåŠå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experimental process and main findings of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects (like humans, animals, or cells), and arrows or flow lines to show the experimental steps. Include a section labeled 'Main Findings' highlighting protective effects or changes observed. Use a white or light-colored background with soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  }
]